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ABSTRACT OF THE DISSERTATION
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by
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Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2011
Professor Igor R. Efimov, Chairperson

Sudden cardiac death (SCD) causes approximately 300,000 - 400,000 deaths a
year in the United States. It usually starts as ventricular tachycardia (VT) and
then degenerates into ventricular fibrillation (VF). Implantable cardioverter
defibrillator (ICD) therapy is the only reliable treatment of VT/VF and has been
shown to effectively reduce mortality by many clinical trials. However, highvoltage ICD shocks could result in myocardial dysfunction and damage. The
majority of patients receiving ICD therapy have a history of coronary disease;
their hearts develop myocardium infarction, which could provide a substrate for
reentrant tachy-arrhythmias. Other than lethal ventricular tachycardia, atrial
fibrillation (AF) became the most common arrhythmia by affecting 2.2 to 5.6
2

millions of Americans. The complications of AF include an increased rate of
mortality, heart failure, stroke, etc.

In this dissertation, we explore mechanisms of sustained ventricular and atrial
tachyarrhythmias and the mechanisms of defibrillation using the conventional
high-voltage single shock. Through the use of novel fluorescent optical mapping
techniques and several animal models of ventricular and atrial arrhythmias, we
develop and validate several novel low-voltage defibrillation therapies for atrial
and ventricular arrhythmias. Several important previous studies on mechanisms
of

arrhythmia

maintenance

and

termination

using

mathematical

and

experimental models are overviewed in Chapter 2. A study on multiple
monophasic shocks improving electrotherapy of ventricular tachycardia in rabbit
model of chronic infarction is presented in Chapter 3. Ventricular arrhythmias
and low-voltage defibrillation therapy are studied in a more clinically-relevent in
vivo canine model of healing myocardial infarction in Chapter 4. Finally, Chapter
5 presents a novel multi-stage low-energy defibrillation therapy for atrial
fibrillation in in vivo canine hearts.
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1

Introduction

1.1 Ventricular Arrhythmia

Sudden cardiac death (SCD) caused by ventricular tachyarrhythmias (VT and VF)
is the most prevalent immediate cause of mortality, which counts for 300,000400,000 deaths per year in the United States 1. SCD most often occurs in patients
with heart disease. In 90 percent of adult victims of SCD, two or more major
coronary arteries are narrowed by fatty buildups. Scarring from a prior heart
attack is found in two-thirds of victims. Patients diagnosed with congestive heart
failure are also at a high risk for SCD.

Three mechanisms underlie the initiation and maintenance of VT: automaticity,
triggered activity, and reentry. Abnormal automaticity causes a region of
ventricular cells to depolarize at an accelerated rate, which overrides sinus
rhythm. Triggered activity refers to action potential generation when oscillations
in transmembrane resting potential reach activation threshold. There are two
forms of triggered activity: early or delayed afterdepolarization. Reentrant VT
requires

specific

electrophysiological

substrates,

including

unidirectional

conduction, functional or structural conduction block, and a region of “slow
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conduction.” Reentrant VTs are often seen in structurally abnormal hearts due to
ischemic or non-ischemic heart diseases. Ventricular scars consist of regions of
dense fibrosis with collagen and fibroblasts. There are also surviving myocyte
bundles overlying on the scars, which are called infarction boarder zone 2. The
dense fibrosis creates conduction block for the formation of reentry circuit 3. The
surviving myocytes form a common pathway or isthmus with slowed conduction
though the scar. Therefore, functional or structural slowed conduction and
conduction block set the stage for sustained reentry VT. Most scar-related
reentrant VT is monomorphic since the reenty circuit is stable and pin to the
infarction border zone of the scar. Although a single scar can support several
different reentrant circuits, a patient with myocardial infarction can have
different morphologies of monomorphic VT 4.
Without cardioversion in time, VT will quickly degenerate to VF, which is driven
by many turbulent wavelets and has a very dynamic and complex pattern of wave
propagation. Transition from VT to VF is due to the increased heterogeneity in
refractoriness of the cardiac tissue induced by acute ischemia or other chronic
heart diseases. Several mechanisms have been proposed to explain the
underlying dynamics of VF. One widely studied mechanism is multiple wavelets
VF and is characterized by the presence of multiple self-sustained electrical
wavelets. Another well-established hypothesis is mother rotor VF, in which VF is
deemed to be driven by one predominant fast source of excitation 5, 6. Preexisting
tissue heterogeneity plays an important role in both hypotheses.

8

Although VF is likely responsible for an overwhelming majority of SCDs, recent
studies from ICD patients indicate that up to 90% of detected spontaneous
episodes of ventricular arrhythmias are either VT or fast VT (FVT) 7. Therefore, in
most instances, ICD therapy can be targeted to treat VT before it degenerates to
VF.

1.2 ICD Therapy for Ventricular Arrhythmias

Over the past two decades, implantable cardioverter defibrillators (ICD) have
become the standard of care for patients at risk for SCD. Multiple multicenter
trials have demonstrated that ICD implantation is the most effective therapy for
SCD

8-11.

Despite the proven efficacy of ICDs in saving lives, at least three

complications have been associated with high voltage shocks. Firstly, high voltage
shocks produce substantial pain, which is often associated with anxiety, fear and
depression, reduced quality of life 12. Secondly, while the majority of ICD shocks
are appropriate, studies estimate that approximately 20 percent of patients with
ICDs may experience inappropriate shocks within about three years of implant in
response to a non-lethal arrhythmia or electrical noise within the device system
13, 14.

Finally, we have shown that ICD shocks could induce myocardial damage via

electroporation

15

evident from post-shock RV endocardial electrograms, which

were linked with increased risk of heart failure and death

9

16.

Sweeney et al

demonstrated that ICD shocked patients have substantially higher ventricular
arrhythmia episode burden and poorer survival compared with anti-tachycardia
paced-only patients

17.

These results indicate that exclusive reliance on high

voltage shocks could degrade ICD survival benefit.

Therefore, lower energy

strategies have been promoted to improve survival and quality of life in ICD
patients. Recent adoption of shock-reduction programming strategies, include
lengthening the number of intervals to detect VF, using more sensitive
supraventricular tachycardia (SVT) discriminators, and employing ATP reduced
shocks by 17 to 28%

18.

However, these efforts to prevent the delivery of shocks

with increased programming have not fully eliminated the need for high energy
shocks to terminate VF or the problems of inappropriate shock delivery for SVTs.
In addition, ICD malfunction has been problematic in the cardiac rhythm
management field. According a recent meta-analysis of industrial reports of
implantable device malfunctions to the FDA from 1990-2002, ICD malfunction
replacement rate is significantly higher than for pacemakers. A detailed
breakdown of causes of malfunctions shows that high-voltage components,
connectors, and circuits are mostly to blame for malfunctions: battery/capacitor
(31.7%), charge circuit (17.4%), connector/header (9.3%), miscellaneous
electrical (24.9%). The difference in reliability between pacemakers and ICDs
appears to come primarily from high-voltage hardware components 19. Thus an
unmet need for low energy electrotherapy challenges current high-energy shock
paradigm.
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Treatments, depending on the severity of symptoms and degree of structural
heart disease, usually combine medications, device implantation, and catheter
ablation. Antiarrhythmic drugs have been disappointing. Catheter ablation is
used for treatment of VT/VF associated with cardiomyopathy as well as
idiopathic VT in structurally normal heart. Focal sources of ventricular
arrhythmogenesis are particularly targeted by ablative therapy. However,
ablation is typically adopted as an adjunct to ICD therapy, because ablation often
fails due to anatomically complex multiple reentrant circuits, harbored within
midmyocardium.

1.3 Atrial Arrhythmia

Besides lethal ventricular arrhythmias, atrial fibrillation (AF) is the most
common arrhythmias encountered in clinical medicine. In 1999, AF affects
approximately 2.2 million adults in the United States 20 and is the most common
sustained heart rhythm disturbance observed in clinical practice. In the same
year, a total of 66,875 deaths with AF as a contributing cause occurred, and a
total of 1,765,304 hospitalizations (137.1 per 1,000 Medicare enrollees) were
reported among persons with AF in the Medicare population.

11

The mechanism of paroxysmal AF is a single or multiple ectopic foci localized
usually around pulmonary veins

21.

This type of AF could be cured by catheter

ablation. However, in chronic AF, the prevailing theory for its mechanism is that
multiple random wavelets of activation coexist to create a disorganized atrial
excitation pattern

22.

There is also a hypothesis that AF may be induced and

maintained by several stable, self-sustained rotors generating exceedingly high
frequency excitation, with fibrillation tissue conduction in atria

23.

Moreover,

after onset of AF, atrial electrophysiological properties changed with time and the
threshold of inducing and sustaining the arrhythmia was lowered. This process
explained AF progression by a process known as electrical remodeling. Other
than electrical remodeling, AF also causes contractile remodeling and irreversible
structural remodeling. Mechanical remodeling manifests as decreased atrial
contractility, which stimulates the structural remodeling due to the remodeled
enlarged atria

24.

The remodeled atrium then becomes an electro-anatomical

substrate to sustain AF by allowing more wavelets with smaller reentrant circuits
with shorter wavelength due to shortening of refractoriness, slowing of
conduction, and an increase in heterogeneity of atrial tissue properties. Different
from ventricular tachy-arrhythmias, the autonomic nervous system has an
important and crucial role in the genesis, maintenance and abruption of AF

25.

This has been attributed to the heterogeneous distribution of vagal innervation
throughout the atria, which increases spatial dispersion of refractory periods.
Although many people live with AF for years, chronic atrial fibrillation is
associated with an increased risk of death. AF can decrease the heart's pumping

12

ability by as much as 20 to 25 percent. Combined with a fast heart rate over a
long period of time, AF can result in congestive heart failure and tachycardiarelated cardiomyopathy. It is also a major cardiac cause of stroke

26.

AF requires

pharmacological and/or electrical shocks to restore sinus rhythm. However,
medication for this arrhythmia has limited effect, and has the potential for
serious side-effects, including promoting ventricular arrhythmias. The external
transthoracic cardioversion for AF involves high-voltage electric shocks, thus
requiring costly hospitalization and anesthesia. Implantable atrial defibrillators
have been previously developed but are not accepted by patients because the
technology employed at that time required high voltage shocks, which exceeded
the patients’ pain threshold.

1.4 Defibrillation Waveforms

In 1899, two physiologists Prevost and Batelli at University of Geneva discovered
that they could defibrillate the heart by applying appropriate high current AC or
DC shocks directly to the surface of the myocardium

27.

In 1947, Claude Beck

successfully performed the first case human internal defibrillation on a pulseless
14-year old boy with exposed chest during surgery. His defibrillator used AC
current directly from the wall socket in operating rooms 28. In 1939, Gurvich and
Yuniev suggested using a single discharge from a capacitor to defibrillate VF in
Soviet Union, thus first introduced DC shock for the purposes of defibrillation 29.
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In the West, scientists and clinicians had been used AC shock for defibrillation
until 1960s. In the United States, in 1962, Lown et al. reported their success in
terminating VT with a single DC monophasic shock in nine patients 30.

Gurvich was the first person who demonstrated the superiority of the biphasic
waveform over the monophasic in dogs in 1967 31, while, John Schuder is the first
person who studied and compared the monophasic and biphasic defibrillation
waveforms in the West in 1980 32. Mirowski and his colleagues produced the first
ICD which then was implanted in a patient at John Hopkins Hospital. Soon after,
ATP was added to the device therapy. Later, Schuder

33

together with Ideker’s

34

continuous work on optimization of biphasic waveform made the contemporary
miniature ICD possible.

Current state-of-the-art ICD therapy is based on low energy ATP followed by a
high-energy shock with biphasic truncated exponential waveform.
biphasic waveform design was based on the Gurvich waveform

35, 36,

Initial

which was

generated by an inductor-capacitor-resistor (LCR) circuit resulting in a damped
sinusoidal waveform. The Gurvich waveform is widely used in transthoracic
defibrillators, which can accommodate large inductors. However, implantable
device size constraints led to adoption of truncated exponential waveforms with
different characteristics 37. The truncated exponential waveform is generated by a
capacitor and high-voltage switch (resistor-capacitor (RC) circuit). Both damped

14

sinusoidal and truncated exponential waveforms have been optimized by
empirical studies varying characteristics of the first and second phases such as
duration: the rise-time and decay of each phase, energy ratio and time delay
between the two phases, etc. Properly optimized biphasic waveforms of both
designs have been shown to significantly decrease the defibrillation threshold

38.

However, truncated exponential waveform is the dominant approach in ICD
therapy due to the size of capacitors and reliability with which a large amount of
energy can be transferred from a battery to a capacitor and then to the heart.
Capacitor-based design allows a reasonably sized device for implantation in the
body.

However, it appears that the existing waveforms were inspired primarily by the
circuit designers, without detailed understanding of the biophysical mechanisms
of defibrillation. From a physiologic standpoint, it is rather clear that the
truncated exponential waveform is not the most efficient way to stimulate cardiac
tissue. For example replacing truncated exponential descending waveform with
an ascending waveform improves DFT by ~15-20% 39, 40. Such an improvement is
incremental but still not enough to justify significant increase in complexity of
the high-energy circuit, which is likely to contribute to malfunctions.

15

1.5 Scope and Procedure of the Dissertation

In this dissertation, we explore mechanisms of sustained ventricular and atrial
tachyarrhythmias and the mechanisms of defibrillation using the conventional
high-voltage single shock. Through the use of novel fluorescent optical mapping
techniques and several animal models of ventricular and atrial arrhythmias, we
develop and validate several novel low-voltage defibrillation therapies for atrial
and ventricular arrhythmias. Chapter 2 will first overview several important
previous studies by several groups on mechanisms of arrhythmia maintenance
and termination using mathematical and experimental models. A study on
multiple monophasic shocks improving electrotherapy of ventricular tachycardia
in rabbit model of chronic infarction is presented in Chapter 3. Ventricular
arrhythmias and low-voltage defibrillation therapy are studied in a more
clinically-relevent in vivo canine model of healing myocardial infarction in
Chapter 4. Finally, Chapter 5 discusses a novel multi-stage low-energy
defibrillation therapy for atrial fibrillation in in vivo canine hearts.

16

2

Defibrillation Therapy towards Lower

Energy

2.1 Virtual Electrode Polarization Theory

When myocardium is exposed to electric field, transmembrane voltage of
myocytes could be altered during the electric stimulus. Some area of the
myocardium is depolarized, where the action potential duration and refractory
period is prolonged; some area of the myocardium is hyperpolarized, where the
action potential and the refractory period is shortened; while the transmembrane
voltage of other area remains the same during shock. The depolarization effect is
caused by virtual cathode. And the virtual anode leads to hyperpolarization.

Electric stimuli affect the cardiac tissue through the mechanism of virtual
electrode polarization (VEP). VEP patterns induced by a single monophasic and a
single biphasic shock were measured and compared by Efimov 41. He discovered
that a monophasic shock induced post-shock epicardial transmembrane
polarization

with

a

highly

nonuniform

polarity-dependent

pattern.

Depolarization (virtual cathode) occurred around the cathode electrode and
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hyperpolarization (virtual anode) appeared close to the anode electrode

41, 42.

Figure 2.1 shows the three types of tissue responses through the VEP effect
produced by the electric shock 43.

Figure 2.1. Three types of tissue responses to virtual electrode polarization: de‐
e.Kcitation. prolongation, and re‐excitation. Maps of shock‐induced polarization and
representative traces superimposed with control action potentials are shown. Shock
was applied from a 1‐cm electrode placed in the left ventricular cavity. Electrical
activity was mapped from the left ventricular epicardium. At the end of a +200‐V
monoplumic shock (upper map), negative polarization produces shortening of
action potential duration (upper blue trace), while positive polarization produced
its prolongation (red trace). A stronger shock (+300 V) resulted in stronger negative
polarization with .subsequent re‐excitation following shock withdrawal (green
trace). (From Efimov et al, J Cardiovasc Electrophysiol, Vol. J I, pp. 339353, March
2000)
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Figure 2.2 The spatial pattern of polarization at the end of the shock produced by a
monophasic shock (+100 V, 7th ms of an 8‐ms shock), optimal biphasic shock
(+100/‐50 V, 15th ms of 16‐ms shock), and nonoptimal biphasic shock (+100/‐200
V, 15th ms of 16‐ms shock). The area of recordings (11.5 mm311.5 mm) is shown by
the red box. Values of polarization are shown relative to the preshock
transmembrane voltage, with red assigned to positive polarization, blue to negative
polarization, and white to areas of no polarization. RA and LA indicate right and left
atrium, respectively; BE, bipolar electrode. (From Efimov et al, Circ. Res.
1998;82;918925)

Then he varied the leading voltage of the second phase of the biphasic shocks
from 0% to 200% that of the first phase

44.

The VEP pattern created by biphasic

shocks with a second phase at below 20% leading-edge voltage of the first phase
produced was similar to that of a monophasic shock. The VEP pattern produced
by biphasic shocks with a second phase at above 70% leading-edge voltage of the
first phase was similar to that of a monophasic shock with an opposite polarity.

19

Post-shock arrhythmias were induced by both of these waveforms. However,
when the amplitudes of the second-phase were from 20% to 70% that of firstphase, the biphasic shocks produced uniform VEPs around zero. This is because
the second phase of the biphasic shock reverses the VEP pattern produced by the
first phase of the shock. Examples of transmembrane voltages maps at the end of
a monophasic shock and two biphasic shocks with different ratios of leading edge
voltage of first phase to that of second phase are shown in Figure 2.2.

The transmembrane voltage of myocardium can be represented in terms of
phase. On the phase map, phase equals to +π where the upstroke of an action
potential is being initiated, while phase equals to -π where the myocardium is
fully repolarized, and the phase is ranged from -π to +π during an action
potential. A phase singularity is defined as a point on the phase map that is
surrounded by a region of activated area, a region of refractory area, and a region
of excitable area. Efimov et al showed that shock-induced phase singularity as a
mechanism of initiation of reentrant activity, thus a mechanism of defibrillation
failure 44. The new waveform (‘Re-excitation’) could be generated at the boundary
between a virtual cathode and a virtual anode when the transmembrane voltage
gradient in these two regions are strong enough and the virtual anode is strong
enough to fully restore the excitability of the myocardium, which is called ‘deexcitation’ effect of the shock

45.

New reentrant circuit could be initiated by the

post-shock waveform, which leads to failure of defibrillation. VEP theory of
defibrillation is the first theory of defibrillation that counts the de-excitation
20

effect of the shock into the mechanism of defibrillation success and failure.

Figure 2.3 Creation of a shock‐induced phase singularity. Electrical activity was
recorded from the area shown in Figure 1 by the red box. The upper left panel
shows the polarization pattern at the end of a 1100/2200‐V biphasic shock (15th
millisecond of 16‐ms shock), which resulted in a single extra beat. The scale is
shown in millivolts, calibrated in the same manner described in Figure 1. The point
of phase singularity is shown with the black circle. The upper middle panel shows a
5‐ms isochronal map, which depicts the initiation of the postshock spread of
activation. The map starts at the onset of the 8‐ms second phase of the shock (phase
reversal). The lower left and lower right panels show optical recordings from
several recording sites used to reconstruct the activation maps: the eight sites
marked with a red arrow correspond to the lower left panel, and the 16 sites
21

marked with a blue arrow correspond to the lower right panel. The upper right
panel shows a continuation of the reentrant activation that follows the middle panel.
Reentrant activity then self‐terminated, after encountering refractory tissue in the
lower right corner of the field of view (see lower right panel traces). (From Efimov et
al, Circ. Res. 1998;82;918925)

Figure 2.3 shows a phase singularity that was created by a shock and a new postshock waveform was generated at the boundary of a virtual cathode and a virtual
anode where has the largest spatial gradient of transmembrane potentials. Based
on the phase singularity mechanism, the optimal defibrillation waveforms should
produce uniform VEPs over the whole heart. And this explains why the
conventional biphasic waveform is superior compared to the monophasic
waveform in defibrillation of VF.

As we mentioned earlier, deexcitation effect of the shock could generate new
wave front propagating from the depolarized area to the excitable area. On the
other hand, the stronger the virtual anode, the more hyperpolarized the
myocardium, which means more sodium channels are available to be activated.
The larger the number of recovered sodium channels, the faster the conduction
velocity is in the area. Therefore, when the excitable region is activated by the
new post-shock wave front generated by the VEP effect, strong deexcitation effect
of the shock could cause fast conduction through the virtual anode region, where

22

the excitable gap in the new reentrant circuit is. Therefore, the excitable gap is
quickly eliminated by the new wave front. The wave front will hit the refractory
region ahead of the excitable gap then vanish, which leads to the success of
defibrillation. From the discussion above, we conclude that we could use the VEP
theory of defibrillation to study and explain the mechanism of defibrillation, as
well as to develop novel waveforms with higher efficacy to achieve low-voltage
defibrillation.

2.2 A Mathematical Model of VEP Unpinning Theory
The VEP pattern including polarization polarity and strength is determined by
the “activating function”,

46

which takes into account the field strength of the

electric stimuli and the conductive properties of the tissue. For a constant field
stimuli, virtual electrode patterns are mainly affected by tissue heterogeneities, 4749

which are scars and other functional and anatomical sources of resistive

heterogeneity. On the other hand, reentrant circuits are shown to be prone to
anchor and to be sustained at functional and anatomical tissue heterogeneities,
where have stronger shock-induced VEP than other normal myocardial areas.
Therefore, a shock with relatively low amplitude will selectively generate VEP at
the areas that provide the substrate for VT/VF. As we discussed in the last
section, a new waveform could be generated at the boundary between virtual
cathode to virtual anode, which is around the rotor of the reentrant circuit.
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Therefore, VT/VF could be terminated with significantly lower energy as
compared to conventional defibrillation, in which the whole heart has to be
excited and synchronized by a high-voltage shock.

Theoretical studies have shown that unpinning of anatomical reentry can be
achieved by a field of 0.5 V/cm when the electric shock is applied at a proper time
with respect to one VT cycle, in contrast to a field >5 V/cm required for high
energy defibrillation

50, 51.

Thus, a ~100-fold = (5V/cm/0.5V/cm)2 decrease in

defibrillation energy can be potentially achieved. The basic concept of the
proposed novel method of defibrillation is illustrated in Figure 2.4. The theory
predicted that unpinning is possible only during a termination window.

Figure 2.4. Mechanisms of unpinning of anatomical reentry by far‐field low energy
shock. Left: Anatomical obstacle (round hole) provides the substrate for stimulus‐
induced hyper‐ and depolarization of cells located at the cathodal and anodal sides
of the obstacle. E = 0.2 V/cm. Such VEP has been shown in experiments. Middle:
Properly timed stimulus given during reentrant activity around the obstacle. The
shock induces VEP (40 ms) which first breaks the rotating wave of excitation and
then causes its unpinning (360 ms). Right: Unpinning electric field E versus phase of
reentry demonstrating existence of termination window. Termination field outside
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the window >10V/cm.

2.3 Mechanisms of Termination of Ventricular
Tachycardia in an in vitro Acute Model of Infarction
Border Zone

Preliminary experiments to assess the new unpinning theory of defibrillation by
our group were first conducted by Ripplinger et al
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in superfused rabbit right

ventricular (RV) free wall preparations (n = 14). The survival of 50-200 µm thick
endocardial layer was verified by phospho-Connexin43 immunohistochemistry.
Reentrant arrhythmias were initiated by burst pacing at an interval of 100-130
ms. Reentry was easily inducible and sustained in all preparations. The number
of sites of anchoring varied from 2 to 8 in various preparations. Monophasic
shocks (10 ms, 0.1-2.1 V/cm) were applied parallel to the endocardium from two
parallel mesh electrodes located in the bath. Time of shock application was varied
throughout the reentrant cycle with circuitry that modulated the time delay based
on a bipolar ECG recording.

Optical mapping of electrical activity in these preparations revealed that shocks
applied during the appropriate phase of the reentrant cycle depolarized a region
near the core of reentry. This area of depolarization serves as a secondary source
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and then creates a new wave front which collides with and annihilates the
reentrant arrhythmia, exactly as predicted in theoretical studies shown in Figure
2.4. An example of termination of reentry by this mechanism is shown in Figure
2.5. In these experiments, a total of 192 reentries were initiated and terminated in
14 in vitro rabbit preparations. Reentries were unpinned/terminated at
E80=1.21±0.2V/cm (field at 80% probability of termination). This is 6.6-fold the
average field excitation threshold. All reentries were terminated at or below 2.1
V/cm. Conventional defibrillation is achieved at E80 = 5.4±0.8 V/cm.40 Thus, the
data suggest that a ~20-fold energy improvement (5.4V/cm/1.21V/cm)2 could be
achieved in comparison to conventional incremental improvements in high
energy defibrillation by 10-30% with the introduction of a new waveform or lead.
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Fig. 2.5. Mechanisms of successful unpinning of anatomical reentry. A: preparation
photograph showing optical imaging field of view (solid black square), location of
reentry core (identified as a stationary line of block/ trajectory of PS), and outline of
phase‐plane maps (dashed black line). Monomorphic ventricular tachycardia (VT)
was maintained by counterclockwise reentry rotating around the line of block. We
imaged the entire ventricular preparation. Tissue above the field of view is atrial
and did not have any communication with ventricular preparation. B: VEP map
showing positive and negative polarization near the line of block/core of reentry as
in Fig. 4. C: optical trace (blue) from site shown with white box in D,1–7. This trace
can be used as a reference to compare the timing of the shock between Figs. 5 and 6.
VT was terminated by a 0.58 V/cm shock (red trace). D: mechanisms of termination
(1–7) show instantaneous phase distributions at time instants marked in C. The
unpinning pulse created a VEP‐induced secondary source of excitation (D,2, red
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arrows) that merged with the reentrant wave (D,3), detaching it from the core. This
unpinned wavefront terminated on reaching the preparation edge. A remnant of the
wave induced by the VEP continued to propagate counterclockwise and self‐
terminated at a refractory area (D,5–7). (From Ripplinger et al, Am J Physiol Heart
Circ Physiol 291: H184–H192, 2006.)

2.4 Mechanisms of Termination of Ventricular
Tachycardia in Rabbit Heart with Chronic Infarction

Arrhythmias are shown to be induced with significantly higher likelihood and
reproducibility in a model of the acute phase of infarction, in as compared to
coronary perfused preparations or intact hearts. However, many sustained
ventricular tachycardia are related with chronic myocardial infarctions and scars
in the clinical setting. It remains to be shown that arrhythmias could be
reproducibly mapped in intact hearts with chronic healed infarct.

Our group has previously conducted a preliminary study in a rabbit model of
healed infarction 53, which fully supports our hypothesis. In this model, infarction
was induced by ligature of the left marginal artery. Animals were allowed to
recover for 6-14 weeks prior to the study. Ripplinger et al

54

studied the

mechanism of induction and termination of ventricular arrhythmia in this model
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using panoramic optical mapping technique. As shown in Figure 2.6, crowded
isochromes in activation maps were observed during sinus rhythm and RV
endocardial pacing at surviving endocardial infarction border zone, which is
typical in this rabbit model of chronic infarction.

Figure 2.6 Characteristics of a typical chronic MI rabbit heart. A, B: Heart surface
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and corresponding 2D projection activation maps during RV pacing. The solid white
line indicates the septum. The dashed white line indicates the infarct region. Asterisks
indicate the infarct region from which signals in panel H correspond. C, D: Heart
surface and corresponding 2D projection activation maps during sinus rhythm. E:
Masson trichrome histology of short axis slices from apex to base. Scar tissue in
infarct region is blue. F: Photograph of anterior view of heart. Infarct region is white
tissue near apex. G: High resolution histology image corresponding to red box in
panel E. The red arrows indicate thin layer of surviving endocardial BZ. G: Optical
action potentials (Vm) and dVm/dt from locations indicated with asterisks in panels
A and B during RV endocardial pacing. A black dot indicates dVm/dtmax on each
signal. (From Ripplinger et al, Heart Rhythm 2009;6:87–97)

All the shocks in this study were delivered from two mesh electrodes parallel to
each other located in the Langendorff perfusion chamber, with one facing the
right ventricle and the other facing the left ventricle. The distance between two
mesh electrodes was 10 cm. The VEP patterns generated by 5 V/cm shocks with
opposite polarities are shown in Figure 2.7. Consistent with our previous finding,
the VEP pattern of a monophasic shock is nonuniform, polarity-dependent. And
it is slightly modulated by tissue heterogeneity, which is represented by the
infarction and the infarction border zone in this model. The main mechanism of
sustained ventricular arrhythmia is monomorphic ventricular tachycardia with
cycle length of 174.7 ± 38.4 ms, maintained by a single mother rotor mainly
located at the infarction border zone.
,
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Figure 2.7. Shock‐induced VEP. A: Photograph of anterior view of heart. The infarct
region is indicated with a dashed white line. B: Heart surface and corresponding 2D
projection of shock‐induced VEP for a 5 V/cm LV shock. White solid and dashed lines
indicate septum and infarct region, respectively. C: Optical action potentials
showing positive and negative shock‐induced polarization overlaid onto control
action potentials. Time of shock is indicated with dashed lines. Locations of optical
action potentials are indicated with asterisks on 2D projections in panels B and D.
D: Heart surface and corresponding 2D projection of shock‐induced VEP for a 5
V/cm RV shock. E: Optical action potential from location indicated with a white “x”
in 2D map of panel F showing time of earliest postshock activation, which resulted
in one shock‐induced extra beat. Time of shock is indicated with dashed lines. F:
Heart surface and corresponding 2D projection activation maps of postshock
activation sequence. (From Ripplinger et al, Heart Rhythm 2009;6:87–97)
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Anti-tachycardia pacing (ATP) was shown ineffective in this model. The
cardioversion threshold (CVT) of a single shock was measured for coupling
intervals of approximately 0%, 20%, 40%, 60%, and 80% that of the VT cycle
length. It was found that the minimum and maximum CVT for a same VT
morphology was significantly different when the shock was applied at different
coupling interval of a single VT cycle length. The CVTs at the favorable versus
unfavorable phase for each animal were determined and were found to be 7.75 ±
1.89 V/cm versus 4.13 ± 1.55 V/cm (P = 0.005).

Figure 2.8 shows an example of successful cardioversion of a sustained reentry
VT by a single monophasic shock applied at the favorable phase with strength of
3 V/cm. The shock-induced secondary source (virtual cathodes) generated new
wave fronts that propagated at the direction opposite to the reentrant wave front
and collided with the reentrant wave front. The excitable gap in the reentrant
circuit was completely eliminated. Therefore, the reentry was unpinned from its
anchoring site and the arrhythmia was terminated successfully.

However, this favorable phase or optimal termination window with significantly
lower CVT compared to the unfavorable phases was different for each VT
morphology, and varied with different hearts. It also depends on the size and
location of the infarct, the size and location of the defibrillation electrodes, the
reentrant circuit, etc. It is impossible for us to measure this favorable phase
clinically for individual patient. This explains that why a single monophasic shock
cardioversion requires high energy. And more importantly, new waveforms needs
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to be developed in order to achieve low-voltage cardioversion of VT.

Figure 2.8. Termination of VT by a shock applied at the correct phase. A:
Photographs and heart surface phase maps of anterior and posterior views of heart.
Dashed white lines correspond to infarct region. The solid white line corresponds to
septum. The dashed green line in posterior view corresponds to where the heart
surface map was cut and unwrapped to produce the 2D projection maps. Heart
surface phase maps correspond to t = 0 ms. B: 2D projection phase maps from time t
= 0 to t = 440 ms. One complete rotation of VT can be observed from t = 0 to t = 236
ms. At t = 238 ms, a 3 V/cm shock is applied that terminates VT. Asterisks and
arrows indicate shock‐induced secondary sources of excitation. C: Optical action
potential (black) showing time of shock application (red). (From Ripplinger et al,
Heart Rhythm 2009;6:87–97)
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3

Multiple Monophasic Shocks Improve

Electrotherapy of Ventricular Tachycardia in a
Rabbit Model of Chronic Infarction

3.1 Abstract

Background: Previously, we showed that the cardioversion threshold (CVT) for
ventricular tachycardia (VT) is phase-dependent, when a monophasic shock
(1MP) is used. In this study, we aimed to extend these findings to a biphasic
shock (1BP), and to compare efficacy of phase-independent multiple monophasic
(5MP) and biphasic shocks (5BP).
Methods: Panoramic optical mapping with Blebbistatin (5 μM) was performed in
post-MI rabbit hearts (n = 8). Flecainide (1.64 ± 0.68 μM) was administered to
promote sustained arrhythmias. 5MP and 5BP were applied within one VT cycle
length (CL). Results were compared to 1BP and antitachycardia pacing (ATP).
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Results: We observed monomorphic VT with CL = 149.6 ± 18.0 ms. Similar to
1MP, CVTs of 1BP were found to be phase-dependent and the max vs. min CVT
was 8.6 ± 1.7 vs. 3.7 ± 1.9 V/cm, respectively (p = 0.0013). Efficacy of 5MP was
higher than 1BP and 5BP. CVT was 3.2 ± 1.4 vs. 5.3 ± 1.9 V/cm, for 5MP vs. 5BP,
respectively (p = 0.00027). 5MP vs. averaged 1BP CVT was 3.6 ± 2.1 vs. 6.8 ± 1.5
V/cm, respectively (p = 0.00024). ATP was found completely ineffective in this
model.
Conclusions: Maintenance of shock-induced virtual electrode polarization (VEP)
by multiple monophasic shocks over a VT cycle is responsible for unpinning of
reentry leading to self-termination. Elimination of VEP by shock polarity reversal
during multiple biphasic shocks proved ineffective. A significant reduction in
CVT may be achieved by applying multiple monophasic shocks within one VT CL
or one single shock at the proper coupling interval.

3.2 Keywords

Ventricular tachycardia; Cardioversion; Optical mapping; Infarction

3.3 Introduction
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Prior myocardial infarction (MI) is manifest in 75% of victims.55,

56

The most

common event leading to SCD is ventricular tachycardia (VT) degenerating into
ventricular fibrillation (VF). Sustained VT in patients with chronic MI is
predominately found to be monomorphic VT, which is caused by stable reentry.57,
58

The mechanism of reentry in ischemic heart disease relates to electrical

remodeling at the infarct border zone (IBZ) which refers to the region of
functioning myocytes at the edge of myocardial scars, which is characterized by
slow and more heterogeneous conduction properties.59-61

The risk of arrhythmic death is found to be higher than that of non-arrhythmic
death in patients over a two-year period after MI.62 Radiofrequency catheter
ablation is successfully used to interrupt the reentrant circuit. But there are risks
associated when the patient has to remain in VT for a relatively long period of
time required for the selection of ablation sites. Moreover, VT of other
morphologies may reoccur and cause SCD even if the ablation procedure was
successful.58,
patients

63, 64

with

ICD therapy, which is now used as the primary treatment in

serious

ventricular

arrhythmias,

has higher efficacy than

antiarrhythmic drug therapy in preventing SCD in high-risk post-MI patients.65-68
Therefore, the defibrillation therapy for post-MI patients deserves further studies
and improvements, especially in the model of chronic MI.
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Previously, we have shown that the CVTs of a single monophasic shock (1MP) for
sustained VT, in a model of isolated rabbit RV preparations with acute MI and in
the intact rabbit hearts with chronic MI, depend on the VT cycle length (CL) and
the coupling interval of the cardioversion shock.52, 54

The goals of this study are: 1) to provide deeper insights into mechanisms of
arrhythmia and cardioversion in the rabbit model of chronic MI; 2) to explore
whether the CVTs of a single biphasic shock (1BP) for sustained VT are also
phase-dependent; and 3) to compare the efficacy of phase-independent multiple
monophasic and biphasic shocks in this infarct rabbit model.

3.4 Materials and Methods

3.4.1 Survival Surgery

The experimental protocol was approved by the Institutional Animal Care and
Use Committee of Washington University. Nine New Zealand White rabbits of
either sex were used in this study. The infarction was created by left coronary
ligation during in vivo survival surgery as previously described.53 One rabbit died
of congestive heart failure and subsequent pulmonary effusion 10 days after the
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surgery. Therefore, eight rabbits with chronic MI were used for in vitro
experiments.

3.4.2 Heart Preparation

Rabbits were allowed to heal for an average of 102 ± 41 days before acute optical
mapping experiments. Rabbits were injected intravenously with sodium
pentobarbital (50 mg/kg) and 1000-2000 U heparin and the heart was removed
Langendorff-perfused and optically mapped as previously described.41 To
eliminate the motion artifacts in optical recordings, we used Blebbistatin (5mM,
BB; Fisher Scientific, Fair Lawn, NJ).69

3.4.3 Acute Experimental Protocol

Imaging was performed using a panoramic imaging system as previously
described.70,

71

Flecainide was used to promote sustained (lasting more than 3

minutes) ventricular arrhythmias in rabbit hearts. A dose of flecainide started
with 0.5μM and was increased at a step of 0.5μM until sustained ventricular
arrhythmia could be induced by burst pacing or a multiple shock protocol (4
pulses, 5 V/cm, 130-170 ms coupling interval). For the same VT morphology, five
monophasic shocks (5MP) with duration of 10 ms and five biphasic shocks (5BP)
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with durations of 6 ms for the first phase and 4 ms for the second phase were
applied within one VT CL. The ratio between the 1st and 2nd phase leading edge
voltages was 2:1. Besides 5MP and 5BP, 1BP was also applied at various phases
throughout one CL for the same VT morphology. All the cardioversion shocks
were applied from two external stainless steel mesh electrodes, which were
configured and connected to the pulse generator as previously described.54 CVTs
were determined for each shock waveform. Antitachycardia pacing (ATP, 8
pulses, 88% of VT CL) was applied in 6 hearts, 6 trials per heart.

3.4.4 Data Analysis

A 3D geometry of the heart was reconstructed and optical signals were registered
with the epicardial surface as previously described.70, 71 The epicardial geometry
is represented by spherical coordinates (θ, φ, r), where (θi, φi) is an evenly spaced
grid, which can be easily redrawn on a 2D plane. A 2D unwrapped epicardium
map is shown in the middle panel of Figure 3.1. Although unwrapping the 3D
geometry to a 2D plane causes distortion at the apex, the 2D grid is very useful in
calculating and visualizing epicardial data for which the analyses do not involve
distance between data points, for example, the calculation of phase maps. In all
2D unwrapped maps the anterior septum is located in the middle.
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CVTs of different shock waveforms were compared. Comparisons of each pair
were made for the same VT morphology and then averaged for all the
morphologies. A paired Student’s t-test was used, and p < 0.05 was considered
statistically different.

3.5 Results

3.5.1 Initiation of sustained ventricular arrhythmias

Sustained VT could not be induced in this model by either multiple plateau-phase
shocks or burst pacing. All induced ventricular arrhythmias were short-lived
meandering rotors that self-terminated within several seconds. Therefore, we
used flecainide (1.64 ± 0.68 μM) to promote sustained VT. The effective
refractory period (ERP) was 183 ± 11 ms before administration of flecainide, and
increased to198 ± 15 ms thirty minutes after administration of flecainide
(p=0.0005).

Multiple shocks (CL=125-160ms) were the most effective way to induce VT.
Figure 3.1 shows a representative example of initiation of VT by the multiple
shocks. The first shock was applied following 1 minute of continuous pacing
(CL=300ms). The VEP pattern of 1MP (5 V/cm) is shown in Figure 3.1, the
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rightmost one in the middle panel. The first activation map in Figure 3.1 shows
the epicardial activation sequence after a diastolic field excitation. In the first
activation map, the depolarized region was excited first. The wave front spread
across the apex toward the base of the heart and excited the hyperpolarized area.
A counterclockwise reentry close to the infarct region is observed in activation
map 2 and 3. A new wave front was induced by the last shock in activation map 4.
After the shock sequence, a clockwise reentry meandered for a short time and
then stabilized at the IBZ forming a mother rotor (See activation map 5 and 6).
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Figure 3.1: Initiation of a stable VT by multiple shock protocol. Top: Optical signal
(purple) showing that a VT was induced by four monophasic shocks (red, 5 V/cm,
163 ms between each shock). Numbers 1‐6 correspond to the time windows of
activation maps 1‐6 in the lower panels, respectively. Mid: Left panel is a digital
photograph of the anterior view of the heart. Middle panel is the 2D unwrapped
epicardium map. The solid line represents the septum. Infarct region is indicated
with a dashed line. Right panel is a 2D unwrapped map of shock‐induced VEP for a 5
V/cm 1MP. Bottom: Six successive activation maps show the process of the
initiation of a stable reentrant circuit. Left column shows anterior view of 3D
activation maps. Right column contains 2D unwrapped activation maps.

3.5.2 Mechanism of sustained ventricular arrhythmia in
CMI

A total of 95 sustained VTs were induced in 8 hearts. They were monomorphic
VTs with CL=149.6±18.0ms. We identified 28 different ECG morphologies of VT
(3.5±0.9 VT morphologies per heart). A mother rotor, anchored to the infarct
region, was the primary mechanism of sustained VT in 89% (25 of 28)
morphologies. Figure 3.2 shows phase maps and Lead I ECG recordings of two
main VT morphologies (56% inductions for the clockwise reentry and 22%
inductions for the counterclockwise, respectively) in a representative heart.
Similar patterns were observed in all hearts.
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Figure 3.2: Two main morphologies of sustained stable VT in one heart. A.
Photograph of anterior view of heart. Infarct region is white tissue from mid LV to
apex. B. 3D phase maps of stable reentrant VTs rotated clockwise and anchored at
IBZ. C. Lead I ECG during clockwise VT. This was the predominant VT morphology
which appears at 56% inductions. The small peak which appeared every three beats
indicates 3:1 retrograde excitation of atria during VT. DF. Similar panels as A,B, and
C only for a second primary VT morphology (22% inductions) which was counter‐
clockwise.

3.5.3 Efficacy of Antitachycardia Pacing (ATP)

All ATP trials failed to terminate the sustained VT.
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3.5.4 Termination of sustained VT by a single biphasic
shock

Figure 3.3 shows an example of 1BP applied at an appropriate phase, and
terminated a sustained stable VT after three post-shock extra beats. The shock,
with an amplitude of 4 V/cm, was applied at t=160ms when the reentry wave
front just arrived at the apex. The shock-induced secondary source generated a
new wave front propagating in the direction opposite to the reentry wave front.
The excitable gap in the reentry circuit was completely eliminated, and the
reentry detached from the IBZ anchoring site. After the unpinning of the reentry,
the arrhythmia meandered for three extra beats and then self terminated.

Figure 3.4 shows an example of cardioversion failure, when the shock was
applied at the inappropriate phase of the reentry. As shown in the phase map at
t=264, a shock, with a strength of 4 V/cm, was applied when the reentry wave
front spread most of the right ventricle, and was about to turn around toward the
left ventricle. The posterior and lateral RV base was excited simultaneously by the
shock-induced VEP effect and the reentry wave front. However, there existed a
large excitable area in the clockwise propagation direction of the reentry wave
front, at the anterior RV base, after the shock at t=276 ms. Moreover, the greater
refractory area in front of the reentry wave front at t=320 ms, compared to the
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same phase of VT at t=40 ms, became fully excitable at t=360 ms. Therefore, the
reentry persisted and the shock failed.

Figure 3.3. Termination of stable VT by 1BP applied at the proper phase. Heart and
VT morphology correspond to Figure 3.1 and 2. Top: Optical action potential (blue)
shows that VT terminated after 1BP (red, 4 V/cm, t=160 ms). Lower panels are 2D
wrapped phase maps from t=0 to t=780 ms. Asterisks indicate shock‐induced
secondary sources. Arrows represent the directions of the wave front propagation.
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Figure 3.4. Failure of cardioversion due to the improper application time of 1BP.
This VT had the same morphology as that in Figure 3.3. Top: Optical action potential
(blue) shows the cardioversion failure of a 1BP (red, 4 V/cm, t=266 ms). Lower
panels are 2D wrapped phase maps.

Figure 3.5 shows an example that an inappropriate application time requires a
higher CVT. As shown in the phase map at t=280 ms, the shock with a strength of
8 V/cm is applied at the same phase of reentry as that in Figure 3.4. In the phase
map at t=291 ms right after the shock, we observe two regions, which were
effected by the shock-induced VEP. Besides the depolarized region (red), there is
a hyperpolarized region (blue) at the anterior LV and RV base. A faster
conduction occurred in this example, compared to the one shown in Figure 3.4,
because a stronger shock produces deeper deexcitation.43 Therefore, the rapid
propagation through the excitable regions, which is shown in the phase map at
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t=300 ms, led to the elimination of excitable gaps soon after the shock and
therefore a successful unpinning. The arrhythmia self-terminated after
meandering for two extra beats.

Figure 3.5.

Termination of stable VT with improper application time of

cardioversion shock requires higher energy. This VT had the same morphology as
previous figures. Top: Optical action potential (blue) showing that VT was
terminated by 1 BP shock (red, 8 V/cm, t=281 ms). Lower panels are 2D wrapped
phase maps.
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Figure 3.6 shows a representative plot of coupling intervals versus CVTs of 1BP
for one VT morphology, after recalculating the actual shock application time and
the exact VT CL. In this example, the minimum CVT is 5 V/cm at 29%, while the
maximum CVT for this VT morphology is more than 10 V/cm since the shock
strength of 10 V/cm failed at 4% of CL. This difference in CVTs is significant in all
eight hearts, where the maximum vs. minimum CVT of 1BP applied at various
phases was 8.6 ± 1.7 vs. 3.7 ± 1.9 V/cm, respectively (p=0.0013). Therefore,
similar to our previous results on 1MP, the CVTs of 1BP are phase-dependent and
the appropriate time of shock (reentry vulnerability window) varies with the VT
morphology.
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Figure 3.6. Plot of the application phases of the shock versus CVTs with 1BP for the
VTs with a same morphology. The application phase varied within one VT CL. Shock
strength started with 1 V/cm and was increased by 1 V/cm until VT was terminated
or the shock strength reached the maximum amplitude we could deliver (10 V/cm).
The CVT varied greatly as a function of the application phase.
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3.5.5 Termination of sustained VT by five monophasic and
five biphasic shocks

Due to the phase-dependent efficacy of both 1MP and 1BP, successive multiple
pulses within one VT CL were explored. We used five pulses in order to cover the
whole phase grid which we scanned separately with one single shock. In eight
infarcted hearts, the CVT of 5MP versus 5BP was 3.2 ± 1.4 vs. 5.3 ± 1.9 V/cm,
respectively (p=0.00027).

Figure 3.7 shows the application of 5MP with strength of 4 V/cm terminated a
stable reentrant VT after one post-shock beat. The phase maps from 0 to 120 ms
show a nearly complete VT reentry. As shown in the phase map at t=190 ms, the
depolarized region (red) consumed part of the excitable gap. The remaining four
shocks provided additional depolarization of already depolarized myocardium in
this region via VEP effect. Therefore, the clockwise reentry wave front was halted
when it propagated to the refractory area at t=264 ms, and the wave front
vanished at t=280 ms after the fourth shock.
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Figure 3.7. Termination of VT by 5MP applied within one VT CL. Top: Optical action
potential (blue) shows that VT unpinned and self‐terminated after application of
5MP (red, 4 V/cm, t=177 ms). The first panel below the optical trace is a VEP map
measured from a 1MP shock (5V/cm) applied at the plateau‐phase. The other panels
are 2D unwrapped phase maps.

Figure 3.8 shows an example of a reentrant VT destabilized by the application of
5BP with strength of 5 V/cm. The first biphasic shock excited part of RV, as
shown in the phase map at t=224 ms. The following four shocks prolonged the
refractory period of the same area, which was excited by the first shock. After the
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last shock, the clockwise wave front encountered the refractory region and the
reentry circuit was disrupted and destabilized. However, this arrhythmia selfterminated after meandering for approximately one minute beyond the
administration of the shocks, unlike the one shown in Figure 3.7.

For all the VT morphologies, a maximum CVT of 1BP is higher than that of 5MP:
8.8 ± 1.2 vs. 3.2 ± 1.2 V/cm, respectively (p=0.00001). Interestingly, 5MP has
nearly a two-fold lower CVT than averaged 1BP CVT at 3.6 ± 2.1 vs. 6.8 ± 1.5
V/cm, respectively (p=0.00024). Meanwhile, CVT of 5MP is similar to the
minimum CVT of 1BP at 4.3 ± 1.9 vs. 4.9 ± 2.7 V/cm, respectively (p=0.37).
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Figure 3.8. Destabilization of stable VT by 5BP. Top: Optical action potential (blue)
shows that VT was destabilized after application of 5BP (red, 5 V/cm, t=213 ms).
Lower panels are 2D wrapped phase maps. Termination of this VT was not recorded
in this file. However, it self‐terminated after approximately one minute.
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3.6 Discussion

In this study, we have demonstrated that (1) in accordance with our previous
studies on 1MP, 1BP has a strong phase-dependent efficacy in terminating
monomorphic VT.

52, 54;

(2) an application of 5MP during one cycle of VT may

offer a novel approach to cardioversion, which is not phase dependent; (3) in
contrast to single shock cardioversion, a 5-pulse cardioversion approach is more
efficacious with monophasic shocks compared to biphasic shocks; (4) ATP,
applied from RV endocardium, is not efficacious in this model of VT.

The evolution of defibrillation therapy from its initial discovery by Prevost and
Bettelli included significant work on optimization of the defibrillation
waveform.27 The original study of Prevost and Battelli reported the possibility of
defibrillation by both alternating current (AC) and capacitor discharge energy
delivery. However, during the 1st half of the 20th century, defibrillation studies
were primarily focused on AC defibrillation, including seminal reports on the first
clinical defibrillation in open heart and closed chest configurations.28, 72 Gurvich
was the first to demonstrate significantly higher efficacy of DC defibrillation as
compared to AC, including first monophasic and then biphasic shocks.29,
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Following his lead during the second half of the 20th century, defibrillation
therapy evolution focused on DC shock defibrillation by optimizing the biphasic
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waveform. Yet, multiple pulse electrotherapies remained under investigation in
basic electrophysiology laboratories.74 Success of this approach is evident from
the widespread application of antitachycardia pacing for treatment of VT.

In clinical trials, ATP has been approved in order to terminate 90% of
spontaneous VT with a CL longer than 300 ms.75-77 Wathen MS et al applied 1~3
ATP trains to fast VTs which are defined by a CL 240-320 ms, and successfully
terminated 84% of episodes with mean CL 280-320 ms versus 69% of episodes
with mean CL 240-280 ms.7 However, in this study, ATP applied from RV
endocardium did not terminate the sustained monomorphic VT. Thus, the
efficacy of termination of VT by ATP may well depend on the nature of VT; for
example, the VT CL, the conduction velocity, and the methods used to initiate
VTs. Besides, the location of the pacing electrode, with respect to the
myocardium infarct may also affect the success rate of this therapy.78

Sustained VT could not be induced, in all eight rabbit hearts with chronic
myocardium infarct, without the administration of Flecainide (1.64 ± 0.68 μM),
which is a class IC anti-arrhythmic drug. Flecainide has been shown to have
significant ventricular proarrhythmic effects, such as converting unsustained VT
to sustained VT, by decreasing both the longitudinal and transverse conduction
velocity of ventricular myocardium without blocking the central common
pathway in healing infarcts.79,
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In this study, 95 sustained ventricular
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arrhythmias were monomorphic VT, 89% of which are observed to be rotors
anchored to IBZ. We also observed shock-induced polymorphic VT whose rotor
kept meandering until it self-terminated before achieving stabilization at IBZ.
Flecainide slowed the conduction and shortened wavelength, which allowed
circus movement in the dimension of rabbit heart.

Ischemia or hypoxia in

patients also promotes arrhythmia by reducing the conduction velocity.
Therefore, the model in this study can be used to further understand the
mechanism of initiation and termination of VT in the patient with myocardium
infarct under the condition of ischemia and/or hypoxia.

We observed the same phase-dependency of 1BP as 1MP in termination of
monomorphic VT in this model. 1BP applied at the appropriate phase could
successfully unpin the VT reentry with relatively low shock strength by creating a
new post-shock wave front that activates all the excitable gaps in the loop ahead
of the reentry wave front. Consequently, the VT self-terminated after several
extra beats (Figure 3.3). For 1BP applied at an inappropriate phase, it fails
because it could not eliminate all the excitable gaps (Figure 3.4). It could also fail
by changing the VT morphology instead of terminating it. However, with higher
shock strength, an improperly-timed biphasic shock could unpin reentry by
causing rapid propagation through newly excitable regions, which results in the
elimination of excitable gaps and successful cardioversion (Figure 3.5).
Therefore, elimination of the excitable gap by shock-induced depolarization
(Figure 3.3) or hyperpolarization (Figure 3.5) is a crucial way to interrupt the

57

reentrant circuit as well as the main mechanism of cardioversion for this model.
Since the shock-induced VEP pattern is settled, if we could sense the reentry
wave front and apply the shock before the reentry wave front reaches the
depolarized region of the VEP, reentry can be terminated with lower shock
strengths.

In our previous study, the maximum and minimum of 1MP applied at different
phases of VT were found to be: 7.75 ± 1.89 V/cm versus 4.13 ± 1.55 V/cm,
p=0.005.54 We would like to compare the cardioversion efficacy between 1MP
and 1BP in this study. However, each experiment already lasts 8~10 hours
without including the 1MP protocol. Moreover, our animal model is exactly the
same as the previous study. Therefore, we can rely on the results from the
previous study, which suggest that 1BP has a similar efficacy with 1MP.

Due to the phase-dependency of 1MP and 1BP, we studied the phase-independent
multiple pulses. We found that multiple pulses unpinned reentry VT by
maintaining the shock-induced depolarization effect, which sustained the tissue
refractory until the reentry wave front was annihilated. The CVT of 5MP was
approximately one half lower than that of 5BP. This is because the sequential
multiple monophasic pulses reinforce the shock-induced VEP effect, which could
keep the tissue refractory. In contrast, the second phase of the biphasic shocks
reverses the VEP effect of the first phase and prevents maintenance of the

58

secondary source. Therefore, after comparison among 1BP, 1MP, 5BP, and 5MP,
we found that 5MP was phase-independent and the most efficient waveform for
the low-voltage cardioversion of the rabbit heart with MI.

3.6 Study Limitations

In order to optically record the electric activity on the surface of the heart and to
register the optical recordings to the myocardium, we have to use the excitationcontraction

uncoupler,

Blebbistatin.

This

agent

frees

up

adenosine

triphosphate that would be used by contraction and thus improves metabolic
state of the heart including possible protection against arrhythmia.

Our fluorescence optical mapping system only allows us to study the action
potentials from epicardium. The electric activity of septum and endocardium
cannot be mapped. Therefore, those intramural reentry circuit or post-shock
breakthrough cannot be explored in this study.

In order to panoramically map the whole ventricular surface of the rabbit heart,
the spatial resolution is reduced to approximately 1.7 x 1.7 mm2, which is
relatively low with respect to the size of a single myocardial cell. Each channel of
photodiode array also collects optical signal scattered from neighboring tissues
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due to the light scattering effect. Moreover, the infarct region contains largely
fibrotic scars intermingled with surviving myocardial fibers and adhesions from
the pericardium caused by the surgery. Therefore, the signal from the infarct
region has lower signal-to-noise ratio than normal tissue.
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4

Low Voltage Multiple Shock Therapy of VT

in Canine Hearts with Healing Infarction

4.1 Abstract:

Introduction: ICD therapy is the most reliable treatment of ventricular
arrhythmias in high-risk post-myocardial infarction (MI) patients. However,
high-voltage shocks may induce local injury current and contribute to the
progression of heart failure. Previously, we achieved a significant reduction in the
cardioversion threshold (CVT) by applying five monophasic (MP) shocks within
one ventricular tachycardia (VT) cycle length (CL) in a rabbit model of chronic
infarct. In this study, we aimed to extend these findings to a more clinically
relevant canine model of healing infarct and to optimize the number of the
multiple pulses.

Methods: The left anterior descending artery of mongrel dogs (n=20) was
occluded for two hours then reperfused via a left lateral thoracotomy. Four days
later, median sternotomy was performed and the animal was placed on
cardiopulmonary bypass. An 8 French pace/sense/shock lead was placed in the
right ventricular (RV) apex and a 15 cm2 epicardial patch was sewn to the
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posterior left ventricle (LV). Epicardial mapping was performed in X dogs using
a custom-made multi-electrode sock.

VT was induced by programmed

stimulation, and defibrillation thresholds (DFT) of therapies delivered from the
RV lead to LV patch were determined using a voltage-regulated step-up protocol.
1 MP shock was applied at 0, 20, 40, 60, 80% coupling interval of one VT CL to
determine phase dependency of the DFT. DFT of 3, 5, 7 MP shocks or 10 MP
shocks applied within one or two VT CLs, respectively, were compared to a single
MP shock. Efficacy of anti-tachycardia pacing (ATP) applied from the RV bipolar
lead was also examined.

Results: One dog died suddenly one day after MI, and in one dog we were only
able to induce polymorphic VT. Of the eighteen remaining dogs, sustained VT
with averaged CL of 177 ± 40 ms was reproducibly induced in ten dogs (n=10).
We identified a total of 26 different surface ECG morphologies of monomorphic
VT in these ten hearts, yielding an average of 2.6 ± 0.8 distinct morphologies per
heart. The DFT of a single MP shock was phase-dependent, ranging from a
minimum of 0.3 ± 0.2 J to a maximum of 5.9 ± 2.5 J (p = 0.008). 10MP shocks
applied in 2 VT CLs achieved the lowest DFT (0.04 ± 0.02 J), compared to 3, 5 or
7 MP shocks applied in 1 VT CL (0.13 ± 0.09, 0.08 ± 0.04, 0.09 ± 0.07,
respectively, p < 0.001). 10MP shocks reduced maximum CVT by 99% compared
to 1MP (0.08 ± 0.09 vs. 5.9 ± 2.5 J, p = 0.007). The success rate of ATP was
12.1% overall.
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Conclusions: Our results suggest that a major reduction in energy can be
achieved by using multiple shocks rather than a single shock to terminate
monomorphic VT. And for stable reentry VT, multiple shocks are much more
efficient than ATP in destabilizing the reentrant circuit.

4.2 Key Terms
Ventricular tachycardia, low-voltage, cardioversion, canine, infarct

4.3 Introduction
Sudden cardiac death accounts for 300,000 to 400,000 death annually in the
United States

81,

most commonly due to ventricular tachyarrhythmias such as

ventricular tachycardia (VT) and ventricular fibrillation (VF). More than 80% of
victims of sudden cardiac death suffer from coronary artery disease (CAD)

82.

Significantly, the most common sustained ventricular arrhythmia in patients with
prior myocardial infarction is re-entrant monomorphic VT 4.

Anti-arrhythmic drug (AAD) and implantable cardioverter-defibrillator (ICD)
therapies remain the major tools for the prevention and termination of lifethreatening ventricular tachyarrhythmias.
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Several randomized, prospective

clinical trials have demonstrated the superiority of ICD therapy to AAD therapy
to

decrease

mortality

tachyarrhythmias

in

patients

65, 67, 83, 84,

with

increased

risk

of

ventricular

including patients with coronary artery disease or

prior myocardial infarction 66, 68, 85. However, high voltage ICD shocks have been
shown to reduce the quality of life and are associated with an increased risk of
mortality

86-88.

Anti-tachycardia pacing (ATP) can reduce the morbidity of ICD

shocks, and was shown to terminate 78% to 94% of VT episodes with cycle
lengths longer than 320 ms

77, 89, 90,

however the efficacy decreased (41% -79%)

and the probability of accelerating tachycardia increased (5-55%) when targeting
VT with cycle length shorter than 300 ms

91, 92.

Catheter ablation is another

common treatment of sustained monomorphic VT. However, VT with multiple
morphologies recurs in 19-50% of the patients. Besides, the procedure requires
patients remain in sustained VT for a relatively long period of time, which might
cause procedure mortality and many other major complications 93.
In this study, we adopted a well-established canine model

94-96

of inducible

monomorphic VT following myocardial infarction reentrant circuits are sustained
by slow and anisotropic conduction that occur in the epicardial border zone 97, 98.

Previously, we showed that the cardioversion thresholds (CVT) of single
monophasic (MP) and single biphasic (BP) shocks varied significantly depending
upon the phase of the VT cycle in which it was delivered, using a rabbit ex vivo
chronic myocardial infarction model of VT

54, 99.

The optimal phase of shock

delivery was determined empirically, not a priori. Importantly, we overcame this
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limitation by applying multiple monophasic (MP) shocks within one VT cycle
length, which reduced the cardioversion threshold (CVT) significantly relative to
single shocks 99. Mechanistically, we demonstrated that this multiple low-energy
shock therapy acts to keep a small area of excitable gap depolarized until the VT
wavefront collides with it, as opposed to depolarizing a large area by a single
high-energy shock. The goal of this study was to extend these findings to a more
clinically relevant canine model of healing infarction and to optimize the number
of shocks for the low-energy multiple-shock therapy.

4.4 Methods
4.4.1 Surgical Procedures

Mongrel dogs (N=20) of either sex weighting 20-25 kg were induced with
propofol (7.5 mg/kg intravenously), maintained on inhalation anesthetic (2-3%
isoflurane in oxygen) while a lateral thoracotomy was performed.

The left

anterior descending (LAD) coronary artery immediately distal to the first
diagonal branch was occluded by ligation for 2 hours, followed by reperfusion to
create an MI.

In cases where the LAD was continuous with the posterior

descending artery, the LAD was also ligated at the apex. Lidocaine (2 mg/kg
bolus over 10 minutes) was given prior to LAD ligation and again prior to
reperfusion to limit ventricular arrhythmias. The surgical procedures have been
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described previously

94.

The right femoral artery was cannulated for continuous

blood pressure monitoring and periodic measurements of pH and electrolytes.
One animal died suddenly one day after infarction.

In the remaining 19 dogs, defibrillation studies were performed 4 days after
infarction. Each animal was re-induced and anesthetized similarly, and a right
femoral arterial line was placed. Median sternotomy was performed and the
heart was exposed in a pericardial cradle. After systemic heparinization (target
activated clotting time > 300 sec), the animal was placed on cardiopulmonary
bypass in order to maintain stable hemodynamics during sustained VT.

4.4.2 Electrode Configuration

As shown in Figure 4.1A, an 8 French lead with a single 5.5 cm distal shock coil
and pace/sense bipole (St Jude Medical, St. Paul, MN) was implanted into the
right ventricle (RV) for delivery of shock and pacing therapies. A defibrillation
patch (15 cm2) was placed over the epicardial surface of the posterior left
ventricle (LV).

A bipolar button electrode was sewn to the anterior LV

epicardium for ventricular sensing.

Continous surface electrograms were

recorded during each experiment.
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In 2 dogs, we mapped the VT circuit using a custom made 253-pole electrode
sock that was sewn to the anterior LV. The sock covered the infarct border zone
as shown in Figure 4.1B. 253 unipolar ventricular electrograms (VEG) with 3-5
mm interelectrode distance were then recorded in sinus rhythm and during VT.
After the placement of electrodes, ventricular shock excitation thresholds (SET)
were measured using a 10 ms monophasic square wave delivered from RV coil to
LV patch and vice versa during the diastolic interval.

Figure 4.1. Electrode patch and epicardial activation map during pacing
(CL=300ms). Position of 253‐pole sock electrode used to map the reentrant VT
circuit seen in (A) RAO and (B) LAO views. RV, right ventricle; LV, left ventricle.

4.4.3 Induction of Ventricular Tachycardia
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To promote sustained VT (lasting more than 30 seconds) in this model, we
administered loading (2 mg/kg) and maintenance (0.05 mg/kg/min) infusions of
flecainide acetate (Sigma-Aldrich, St. Louis, MO) intravenously. Ventricular
effective refractory period (ERP) was measured before and after flecainide
administration. Ventricular arrhythmia was induced by programmed stimulation
delivered through the endocardial RV bipole via a stimulus isolator (A365R;
World Precision Instruments, Sarasota, FL).

VF was defined as a ventricular rate exceeding 500 bpm (cycle length shorter
than 120 ms) with disorganized ECG morphology. In all experiments, VF was
terminated using an external defibrillator that delivered a single biphasic shock
across the heart via hand-held paddles (Heartstart XL, Philips Electronics,
Amsterdam, Netherlands).

After each successful external defibrillation,

induction of VT was withheld for five to ten minutes to allow recovery of the
myocardium.

4.4.4 Defibrillation Waveforms

All defibrillation therapies were delivered from the RV lead-LV patch vector. A
single monophasic shock (1MP, 10 ms) was applied at various phases (0%, 20%,
40%, 60%, 80%) of one VT cycle length to determine the phase-specific DFT.
The DFT of three, five or seven monophasic shocks applied within one VT cycle
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length (3MP, 5MP and 7MP, respectively), or ten monophasic shocks delivered
within two VT cycle lengths (10MP) were compared to that of a single MP shock
(Figure 4.2). DFT was defined as the shock amplitude, in volts, that terminated
the VT.

The DFT for each therapy (1MP, 3MP, 5MP, 7MP, 10MP) was

determined sequentially, and the cycle was then repeated until the experiment
was terminated.

DFTs were determined using a voltage-regulated up-down

protocol in which the amplitude of the shock voltage was increased in 20%
increments beginning at twice the shock excitation threshold until cardioversion
was achieved. Once a DFT for a given therapy was determined, subsequent
attempts were begun at 80% of the previous DFT. 1MP shocks were delivered
from an external defibrillator (Ventritex, Sunnyvale, CA). All multiple-shock
therapies were delivered by a custom built LabVIEW software program (National
Instruments, Austin, TX) and amplified by a computer-controlled, regulated
power supply (BOP 100-4M; Kepco, Flushing, NY).

The impedance was

measured using a current probe (A622; Tektronix, Inc., Beaverton, OR).
Antitachycardia pacing (ATP; eight pulses with an interval of 88% of VT cycle
length) was applied in all animals through the RV endocardial bipolar pacing
lead.
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Figure 4.2. CVTs of all Shock waveforms were measured and compared. 1MP: one
monophasic shocks that applied at different coupling interval of the VT CL. 3MP,
5MP, 7MP: three, five, and seven monophasic shocks that applied within one VT CL.
10MP: ten monophasic shocks applied within two VT CL.

4.4.5 Data Analysis

Local activation times were defined as the time of the maximum negative
derivative in each unipolar VEG. All VEGs were edited visually to verify accuracy
of the computer-recognized activation times. Activation maps were constructed
using the isochrones of the activation times for all VEGs.
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The minimum and maximum CVTs of 1MP shock, the maximum CVTs of 1MP
shock and that of 10MP shocks were compared using an unpaired Student’s ttest. CVTs for multiple shock thereapies (3MP, 5MP, 7MP, and 10MP) were
compared using one-way analysis of variance (ANOVA). Results are reported as
mean ± standard deviation. A p value of ≤ 0.05 was considered statistically
significant. All statistical analyses were performed using SPSS (Version 19, IBM,
Somers, NY).

4.5 Results

4.5.1 VT in Canine Hearts with 4-day Infarct

Flecainide infusions allowed us to reproducibly induce sustained monomorphic
ventricular tachycardia in ten of nineteeen dogs (52.6 %). One dog did exhibited
only sustained polymorphic VT. The ventricular effective refractory period was
significantly prolonged by administration of flecainide (155 ± 19 ms vs. 172 ± 18
ms, p = 0.002). VT cycle lengths ranged from 120 to 250 ms (mean CL 177 ± 40
ms). We identified a total of 26 different ECG morphologies of monomorphic VT
in the remaining ten hearts (an average of 2.6 ± 0.8 VT morphologies per heart).

71

Activation maps were constructed during initiation of VT by programmed
stimulation. While induced monomorphic VT had uniform cycle length and
stable QRS morphology, in some cases, initial ventricular depolarizations after
delivered extrastimuli exhibited variable cycle length and QRS morphology. An
example is shown in Figure 4.3. Crowding of isochrones and conduction
slowing is observed at the infarct region during RV endocardial pacing at a cycle
length of 300 ms. We observed lines of conduction block after delivering
premature stimuli with a coupling interval of S1/S2=300/165 ms and during
sustained reentry, but not during pacing at 300 ms. This suggests that the
epicardial border zone provided functional conduction block and acted as the
substrate to sustain the reentrant circuit.

Figure 4.3. Initiation of VT by a pacing train followed by a single premature stimulus. A:
Ventricular electrogram (VEG) during induction of VT. B-D: Epicardial activation maps
with isochrones drawn in 15 ms increments were constructed in the time window outlined
by the white box during (A) RV endocardial pacing at a cycle length of S1=300 ms, (B) a
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premature stimulus at a coupling interval of S2=165 ms and (C) beginning of reentrant
VT. The directions of wave front propagation are shown with arrows. Lines of
conduction block in the reentrant circuit are denoted with bold dashed lines in C and D.

4.5.2 Anti-tachycardia Pacing (ATP)

ATP terminated VT in only 12 of 99 trials, with a success rate of 12.1% in a total of
eleven hearts. Two ATP trials (2%) converted VT to VF.

4.5.3 Ventricular Shock Excitation Threshold

Ventricular shock excitation thresholds (SET) were measured for both polarities
during sinus rhythm. The SET of RV anodal shock was significantly lower than
that of RV cathodal shock (1.0 ± 0.7 V vs. 1.5 ± 0.9 V, p = 0.017).

4.5.4 Cardioversion Thresholds of a Single Monophasic
Shock

Figure 4.4 is an example of a 1MP shock, applied at an optimal phase,
terminating sustained monomorphic VT after one extra beat. The shock, with a
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DFT of 0.1 J, was applied when the re-entrant wave front slowly entered the
isthmus of the figure-of-eight reentry circuit. After shock application, the earliest
epicardial breakthrough appeared at the RV base. The line of conduction block
disappeared during the postshock beat which has a wider cycle length at 290 ms.
After an isoelectric interval of 703 ms, sinus rhythm was restored. This finding
demonstrates that reentrant circuits in this canine model of healing MI are
sustained by functional conduction block at the epicardial border zone.

Figure 4.4. A single monophasic shock with an amplitude of 25 V, was delivered at
an optimal phase of the VT cycle and terminated a sustained VT with cycle length of
209 ms.

Figure 4.5 is an example of a 1MP shock applied at a suboptimal phase.
Although this shock does terminate VT, it does so only after eight extra beats.
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Termination by this shock also required much higher energy (DFT = 6.0 J). Two
lines of conduction block are shown in Figure 4.5 B with black dashed lines.
Eventually, the lines of conduction block disappeared during the post-shock extra
beats, and the stable reentrant circuit was destroyed by the shock, restoring sinus
rhythm.

Figure 4.5. A single monophasic shock with an amplitude of 190 V was delivered at a
sub‐optimal phase of the VT cycle terminated a sustained VT with a cycle length of
215 ms after eight post‐shock extra beats. Shock eliminated the lines of conduction
block by creating secondary sources via VEP effect.

Figure 4.6 shows a representative plot of shock application phases versus DFT
of 1MP shock in one animal. Here, the minimum CVT is 0.42 J at 40% of the VT
CL, whereas the maximum DFT for this animal is 5.1 J at 0% of the VT cycle
length. This phase dependency of DFT was seen in all five hearts in which phase
75

dependency of DFT was tested. Overall, the minimum versus maximum DFT of
1MP shock applied at various phases was 0.3 ± 0.2 J versus 5.9 ± 2.5 J,
respectively (p = 0.008). The optimal phase of shock application varied with
different animals.

Figure 4.6. CVT of a single shock is phase dependent. A: Single monophasic shocks
were delivered at 0%, 20%, 40%, 60% and 80% of the VT cycle length, indicated by
the solid vertical lines.

B: CVT as a function of phase of VT, in Joules. EKG,

electrocardiogram; VT, ventricular tachycardia; CL, cycle length; CVT, cardioversion
threshold.
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4.5.5 Cardioversion Thresholds of Multiple Shock Therapies

For multiple shock therapies, DFT, in Joules, was calculated by multiplying the
energy of a single shock by the number of shocks that applied. In Figure 6A, a
1MP shock with energy of 1.1 J failed to terminate VT with a cycle length of 220
ms. In the same animal, for a faster VT with cycle length of 170 ms, 3MP, 5MP,
7MP, 10MP successfully restored sinus rhythm with DFTs of 0.24 J, 0.16 J, 0.2 J,
and 0.06J, respectively.

Figure 4.7 shows representative examples of

cardioversion by a single monophasic shock and by multiple shock therapies with
different number of shocks.
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Figure 4.7. Representative Examples of Single‐ and Multiple‐Shock Therapies. A:
An 80V single monophasic shock failed to terminate VT.

The cardioversion

thresholds of (B) 3 monophasic shocks, (C) 5 monophasic shocks, (D) 7 monophasic
shocks delivered within one VT cycle length and (E) 10 monophasic shocks
delivered within two VT cycle lengths are shown.

The mean DFTs of multiple shock therapies are shown in Figure 4.8. 10MP
shocks, applied in two VT cycle lengths, achieved the lowest DFT with respect to
both shock amplitude and total energy (4.9 ± 1.2 V and 0.04 ± 0.02 J,
respectively) compared to 3MP, 5MP, and 7MP shocks applied within one VT
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cycle length. Amongst multiple shock therapies, 3MP applied in one VT cycle
length had the highest DFT (15.3 ± 6.3 V and 0.13 ± 0.09 J). Importantly, the
maximum DFT of 1MP in each animal remained significantly higher than that of
any of the multiple shock therapies. For example, maximum DFT of 1MP
compared to that of 10MP shocks was 5.9 ± 2.5 J versus 0.08 ± 0.09 J,
respectively (p = 0.007). Moreover, there was no significant difference between
the maximum and minimum CVT measured in every animal for each multiple
shock therapy.

Figure 4.8. Cardioversion Thresholds of Multiple Shock Therapies.

The

Cardioversion Thresholds in (A) Voltage and (B) Energy are shown for 3, 5 and 7
monophasic shocks (3MP, 5MP and 7MP, respectively) delivered within one VT
cycle length and 10 monophasic shocks (10MP) delivered within two VT cycle
lengths.
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4.6 Discussion

In accordance with our previous studies on a single monophasic and a single
biphasic shock in an ex vivo chronic myocardial infarction rabbit heart model of
VT, the DFT of 1MP shock is highly phase-dependent for terminating
monomorphic VT in the in vivo healing infarction canine model of VT.
Unfortunately, the optimal phase of the VT cycle in which 1 MP shock can
terminate VT varies from animal to animal.

Significantly, multiple shock

therapies applied during one or two VT cycle lengths overcomes this phasedependency and terminates monomorphic sustained VT with significantly more
efficacy than a single shock. Amongst the multiple shock therapies tested, 3MP
shocks delivered within one VT cycle length had the highest DFT, whereas 10MP
shocks delivered within two VT cycle lengths had the lowest DFT (0.13 ± 0.09 J
versus 0.04 ± 0.02 J, respectively, p < 0.001). Finally, ATP therapy, applied from
right ventricular endocardial bipole, terminated VT only 12.1 % of the time in this
model.

We induced sustained monomorphic VT, in ten of nineteen (52.6%) canine hearts
with healing myocardial infarction with the administration of flecainide. Several
groups have shown that the inducibility of sustained VT without flecainide in this
model is relatively low, ranging from 23%~47%

96, 100, 101.

Similar to our

observations, these prior studies demonstrated that the mechanism of VT
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induced by programmed stimulation in this canine model is due to functional
block at a region of the epicardial infarct border zone, thereby creating a
reentrant circuit.

Although the surviving border zone has some normal

histological features, there is also varying degrees of disruption of Connexin43
that occurs in a time-dependent manner, similar to that discovered in healed
human infarcts.

Therefore, the inducibility of sustained VT depends on the

functional properties of the tissue, specifically, the infarct border zone. Peters et
al. showed that a stable reentrant circuit leading to sustained, monomorphic VT
appears to occur only if the lateralization of connexin43 extends throughout the
full thickness of a region in the infarction border zone, which defines the
locations of the lines of conduction block

60.

Coromilas et al. showed that

flecainide converted inducible unsustained monomorphic and polymorphic VT to
sustained monomorphic VT by lengthening the line of block and slowing
conduction in both the longitudinal and transverse direction relative to the
myocardial fiber orientation, whereas not causing complete conduction block in
central common pathway 79.

ATP has conventionally been targeted to only slow, presumably hemodynamically
tolerated VTs. Prior studies have demonstrated that ATP terminates 78% to 94%
of monomorphic VT with cycle length longer than 300 ms, albeit with a 2% to 4%
risk of accelerating VT to VF

102-104.

Wathen et al. tested the efficacy of ATP for

“fast” VT, in which the cycle length ranged from 240 to 320 ms, and found that
ATP terminated 84% of VT episodes with median cycle length 280 to 320 ms
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versus 69% of episodes with median cycle length 240 to 280 ms 91. Other clinical
trials tested ATP for fast VT in ICDs and found 47% to 79% success with a risk of
acceleration to VT of 3% to 10% 77, 90, 92. In this study, however, ATP applied from
right

ventricular

endocardial

bipolar

pacing

lead

terminated

induced

monomorphic VT only 12% of the time. This low success rate is likely due to the
relatively fast VT induced in this model (mean cycle length 177 ms).

The

relatively low success rate of ATP (41% to 68%) for VT induced in the
electrophysiology laboratory has been shown by other studies 105-108. The efficacy
of ATP may also depend on the nature and the mechanism of VT, for example,
functional or anatomical VT, conduction velocity of the wave front, cycle length of
VT, and the methods used to induce VT. The location of the pacing electrode
relative to the location of scar tissue might affect the success rate of ATP.

We showed that the efficacy of a single monophasic shock was phase-dependent
in the canine model of 4-day infarction, which indicates that the DFT could be
significantly decreased if the shock is applied at the optimal phase. This result is
consistent with our previous findings about the defibrillation efficacy of a single
monophasic and biphasic shocks in ex vivo rabbit hearts with chronic myocardial
infarction 54, 109. Specifically, the average maximum DFT of a single shock was 20
times higher than the average minimum DFT in this canine model. The optimal
phase, defined as the delivery phase with lowest DFT, varied between animals
and could not be predicted a priori. However, multiple shock therapies enables
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similarly low DFT as a single shock without requiring knowledge of the optimal
phase.

Previously we studied the mechanism of defibrillation using five monophasic
shocks applied within one VT cycle length in ex vivo rabbit hearts with chronic
myocardial infarction 109. We found that multiple shocks unpinned the reentrant
circuit by maintaining a shock-induced depolarization effect, which increased the
duration of refractory tissue until the reentrant wave front collided with the
refractory tissue and was extinguished. In the same model, we also showed that a
single monophasic shock has equally efficacy as a single biphasic shock, while
multiple monophasic shocks have significantly higher efficacy than multiple
biphasic shocks. This phenomenon occurs because the second (inverted) phase
of a biphasic shock reverses the virtual electrode polarization effect of the first
phase and thus prevents prolongation of refractory tissue. In this study, we varied
the number of shocks for the multiple shock therapy and extended it to a more
clinically relevant in vivo model. We found that 10MP shocks applied within two
VT CL has the lowest DFT compared to 3MP, 5MP, and 7MP shocks applied
within one VT CL. The DFT of 10MP shocks was only five times the ventricular
shock excitation threshold and only one hundredth of that of 1MP shock.
Importantly, in this model, the voltage and total energy required for defibrillation
using multiple shock therapy is comparable to that of ATP, yet with significantly
higher efficacy. Though multiple shock therapy may require design changes prior
to incorporation into implantable cardioverter defibrillators, such therapies could
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be delivered in far less time than a full output ICD shock, which requires the
relatively slow process of fully charging the discharge capacitor.

Moreover,

reducing the number of full output ICD shocks would reduce morbidity and likely
prolong battery life in patients with repeated episodes of monomorphic VT who
fail ATP.

4.7 Conclusions

In the present study, we found that the efficacy of a single monophasic shock in
cardioversion of VT in canine hearts with healing myocardial infarction has a
phase-dependent property. We also showed that multiple shock therapies were
significantly more efficacious for cardioversion of VT than a single monophasic
shock since they don’t display the phase-dependent manner. Importantly, we
showed that ten monophasic shocks applied within two VT cycle lengths achieved
the lowest CVT (4.9 ± 1.2 V; 0.04 ± 0.02 J), which is comparable to the energy of
ATP therapy, which is shown to be ineffective in this model. Based on this study,
we conclude that multiple shock therapy may become the new paradigm of lowenergy cardioversion of VT.
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5

Low Energy Multi-stage Atrial Defibrillation

Therapy

5.1 Abstract

Background: Implantable device therapy of atrial fibrillation (AF) is limited by
pain from high-energy shocks. We developed a low-energy multi-stage
defibrillation therapy and tested it in a canine model of AF.

Methods and Results: AF was induced during vagus nerve stimulation. Our novel
defibrillation therapy consisted of three stages: ST1 (1-4 low energy biphasic
shocks), ST2 (6-10 ultra-low energy monophasic shocks), and ST3 (antitachycardia pacing). Firstly, ST1 testing compared single or multiple monophasic
(MP) and biphasic (BP) shocks. Secondly, several multi-stage therapies were
tested: ST1 versus ST1+ST3 versus ST1+ST2+ST3. Thirdly, three shock vectors
were compared: superior vena cava to distal coronary sinus (SVC>CSd), proximal
coronary sinus to left atrial appendage (CSp>LAA) and right atrial appendage to
LAA (RAA>LAA). The atrial defibrillation threshold (DFT) of 1BP shock was less
than 1MP shock (0.55 ± 0.1 versus 1.38 ± 0.31 J; p =0.004). 2-3 BP shocks
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terminated AF with lower peak voltage than 1BP or 1MP shock and with lower
atrial DFT than 4 BP shocks. Compared to ST1 therapy alone, ST1+ST3 lowered
the atrial DFT moderately (0.51 ± 0.46 versus 0.95 ± 0.32 J; p = 0.006) while a
three-stage therapy, ST1+ST2+ST3, dramatically lowered the atrial DFT (0.19 ±
0.12 J versus 0.95 ± 0.32 J for ST1 alone, p<0.001). Finally, the three-stage
therapy ST1+ST2+ST3 was equally effective for all studied vectors.

Conclusions: Three-stage therapy significantly reduces the AF defibrillation
threshold and opens the door to low energy atrial defibrillation at or below the
pain threshold.

5.2 Key Words
Atrial fibrillation; defibrillation; cardioversion; vagal stimulation

5.3 Introduction

Atrial fibrillation (AF) is the most common tachyarrhythmia worldwide. The
number of Americans afflicted by AF will increase to over 12 million by 2050,110
placing a significant additional burden on the healthcare system. Moreover,
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patients with AF suffer serious consequences including increased rates of
thromboembolic stroke, congestive heart failure, cognitive dysfunction, and
mortality.111-113

Catheter ablation has become increasingly common for the treatment for AF but
its success rate varies widely and it is beset by a significant rate of major and
minor complications. While success rates vary depending upon operator and
patient selection, arrhythmia-free survival rates after a single catheter ablation
procedure are less than 29% at 5 years.114 Complication rates will likely improve
over time, yet risks such as stroke, pulmonary vein stenosis, phrenic nerve injury,
and the rare but often fatal atrioesophageal fistula have made this a less than
ideal treatment modality.115-118

For symptomatic patients, cardioversion of AF to sinus rhythm using highvoltage external shocks, with or without antiarrhythmic drugs remains a
mainstay of therapy. External cardioversion is painful and can lead to brady- and
tachy- arrhythmias, necessitating anesthesia and careful peri-procedural patient
monitoring. Hospitalization, anesthesia, personnel and ancillary procedures costs
associated with AF is estimated to cost Medicare more than $15.7 billion
annually.119
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These considerations have prompted efforts to design an implantable device that
converts AF to sinus rhythm safely.

Such a system would enable rapid

cardioversion soon after the onset of AF, ameliorating symptoms and
importantly, reducing the likelihood of atrial remodeling.120 Moreover, since
internal atrial cardioversion requires significantly less energy than external
cardioversion,121 it may be possible to deliver this therapy below the pain
threshold, generally considered to be between 0.1-1 J.12,13 Several internal atrial
cardioverters have been developed in the past122-124 but received limited
acceptance primarily due to the discomfort associated with shocks.125-130

Experimental and clinical studies have demonstrated that vagus nerve
stimulation promotes sustained AF by decreasing the atrial effective refractory
period (AERP) and AERP rate adaption in an anatomically heterogeneous
manner, thus creating the substrate for maintenance of sustained AF.131, 132 This
acute model readily produces sustained AF and has been used extensively to
study mechanisms of and therapies for atrial fibrillation.133 The AF generated by
this model was shown to be of significantly longer duration and higher dominant
frequency compared to that induced by chronic rapid pacing, making it a
reasonable model to study the electrotherapy of AF.134

Previously, we compared multiple monophasic (MP) shocks to a single shock for
defibrillation of atrial fibrillation and flutter in an ex vivo rabbit model135 and in
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a rabbit chronic infarction model of ventricular tachycardia.109 In both models,
multiple monophasic shocks significantly lowered the defibrillation threshold.
The goal of this study was to develop a low-energy therapy for defibrillation of AF
in vivo.

5.4 Methods

5.4.1 Surgical Procedures

Mongrel dogs (n=16) weighing 20-25 kg were intubated and anesthetized with
propofol (7.5 mg/kg intravenously) and 2-3% inhaled isoflurane in oxygen
(Model 2000; Hallowell EMC, Pittsfield, MA). The right femoral artery was
cannulated

for

continuous

blood

pressure

monitoring

and

periodic

measurements of arterial blood gas and electrolytes. After median sternotomy,
the pericardium was opened to expose the heart. Bilateral carotid cut downs
were performed to isolate the Vagus nerves.

Cuff electrodes (A0004-6,

Evergreen Medical Technologies, LLC, St. Paul, MN) were placed around each
nerve for subsequent stimulation.
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5.4.2 Electrode Placement

Bipolar electrodes were sutured to the right atrium for pacing, and left atrium
and ventricular apex for sensing. Atrial and ventricular epicardial electrograms
(EG) and surface electrocardiogram (ECG) were recorded continuously.

Custom defibrillation disc electrodes 0.5 or 1 inch in diameter were sutured to the
right and left atrial appendages (RAA and LAA, respectively) and superior vena
cava (SVC). A custom 4 French lead with two shock coils, each 1 inch in length,
was placed into the coronary sinus (CS; Evergreen Medical Technologies, LLC, St.
Paul, MN); the proximal and distal coils are referred to as CSp and CSd,
respectively. A schematic of the defibrillation electrodes is shown in Figure 5.1.

After the placement of electrodes, atrial and ventricular shock excitation
thresholds (SET) were measured for each defibrillation electrode pair tested
using a 10 ms square monophasic shock applied during the diastolic interval.

5.4.3 Atrial Fibrillation Induction and Definitions
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Bilateral vagus nerve stimulation was performed with 10-20 V pulses of 1 ms
duration starting at 4 Hz via a stimulator (SD9; Grass, West Warwick, RI). Atrial
effective refractory period (AERP) was measured before and after vagal
stimulation. After 30 seconds of stimulation, AF was induced via right atrial
burst pacing at 10-20 Hz at four times the atrial capture threshold via a stimulus
isolator (A365R; World Precision Instrument, Sarasota, FL). AF was defined as a
rapid, irregular atrial rhythm with varying atrial electrogram morphology.
Frequency of vagal stimulation was increased in 1 Hz steps until AF lasted 10
minutes or longer. If atrial flutter (AFl) was induced, anti-tachycardia pacing
(88% of cycle length) or multiple-shock therapy was applied to restore sinus
rhythm. Vagus nerve stimulation was then resumed with a higher frequency.
After every successful termination of AF or AFl, stimulation was withheld for five
minutes to allow recovery of the nerve.

Figure 5.1. Anatomic Positions of Defibrillation Electrodes. Schematic of a canine
heart with locations of electrodes from which defibrillation therapies were
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delivered depicted. A: right anterior oblique (RAO) view showing superior vena
cava and right atrial appendage disc electrodes. B: left anterior oblique (LAO) view
showing left atrial appendage disc electrode. C: posteroanterior (PA) view showing
distal and proximal coronary sinus coils. SVC, superior vena cava; RA, right atrium;
PT, pulmonary trunk; RV, right ventricle; LV, left ventricle; CSp, proximal coronary
sinus; CSd, distal coronary sinus.

5.4.4 Defibrillation Vectors and Waveforms

After inducing AF, we determined the peak voltages and atrial DFTs of the
waveforms depicted in Figure 5.2A.

Single monophasic (1MP, 10 ms) or

biphasic (1BP, 6/4 ms) shocks, and multiple monophasic (2MP) or biphasic
shocks (2BP, 3BP, 4BP) were delivered across a single vector oriented from RAA
to LAA. In all cases, the initial shock was delivered on the R-wave and triggered
via the ventricular electrogram or surface ECG. The multiple shocks were applied
within 100 ms, which was shorter than the ventricular ERP, to avoid induction of
ventricular fibrillation.

Next, we tested multiple stage defibrillation therapies (Figure 5.2B). Stage 1
therapy (ST1) consisted of two BP shocks (10-100V) applied within a single cycle
length (CL) of AF. The cycle length of AF was determined based on the dominant
frequency of AF induced. Stage 2 therapy (ST2) consisted of 6-10 lower energy
MP shocks applied across the same vector as in ST1.
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All ST2 shocks were

delivered at or above the atrial shock excitation threshold (SET) but below the
ventricular SET, thus capturing atrial but not ventricular tissue. ST2 shocks were
delivered at a rate 70-100% that of the AF CL. Stage 3 therapy (ST3) consisted of
6-10 bipolar right atrial pacing stimuli delivered at 70-100% of the AF CL. The
following combinations of stages were tested: (i) ST1, (ii) ST1+ST3, and (iii)
ST1+ST2+ST3. The delay between each stage was 100-400 ms.

Figure 5.2. Waveforms and Stages of Low Energy Defibrillation Therapy. A:
Individual waveforms tested in Stage 1 (ST1) of the three‐stage therapy. B: ST1+ST3
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therapy. ST1 consists of 2 biphasic shocks delivered within 30‐50% of the AF cycle
length. ST3 consists of 8 bipolar atrial pacing stimuli delivered at 70‐100% of the
AF cycle length. C: ST1+ST2+ST3 therapy. ST1 consists of 2 biphasic shocks. ST2
consists of 8 lower voltage monophasic shocks, and ST3 consists of 8 atrial pacing
stimuli. Each pulse in ST2 and ST3 is delivered at 70‐100% of the AF cycle length.
In both B and C, a delay of 100‐400 ms separates each stage of therapy. MP,
monophasic shock; BP, biphasic shock; AF, atrial fibrillation; CL, cycle length. ST1,
stage 1; ST2, stage 2; ST3, stage 3.

Finally, we determined the atrial DFTs of three defibrillation vectors: SVC to CSd,
LAA to CSp, and RAA to LAA. For each vector, three combinations of therapy
(described above) were tested. All therapies were delivered by a custom built
LabVIEW software program (National Instruments, Austin, TX) and amplified by
a computer-controlled, regulated power supply (BOP 100-4M; Kepco, Flushing,
NY). The impedance of each defibrillation vector was measured using a current
probe (A622; Tektronix, Inc., Beaverton, OR).

5.4.5 Statistical Analysis

The far-field excitation threshold, atrial refractoriness, and frequencies of vagus
nerve stimulation for different atrial tachyarrhythmias were compared using an
unpaired Student’s t-test. Atrial DFTs for each waveform/defibrillation vector
combination were compared using one-way analysis of variance (ANOVA).
Results are reported as mean ± standard deviation. A p value of ≤ 0.05 was
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considered significant. All statistical analyses were performed using SPSS
(Version 19, IBM, Somers, NY).

5.5 Results

5.5.1 Atrial Fibrillation Model

Sustained AF was induced in 12 out of 16 animals. Characteristics of the AF
generated are shown in Figure 5.3. AERP decreased significantly during vagal
stimulation (79.6 ± 8.7 ms vs. 117.1 ± 14.7 without stimulation, p < 0.001). In
general, durations of AF increased with the frequency of vagus nerve stimulation,
and the stimulation frequency that sustained AF was significantly shorter than
that which sustained atrial flutter (AFL; 6.7 ± 2.1 Hz vs. 12.0 ± 4.4 Hz, p = 0.03).
As expected, average dominant frequency of sustained AF was significantly
higher than that of AFl (7.7 ± 0.4 Hz vs. 10.4 ± 1.4 Hz, p = 0.004).
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Figure 5.3. Characteristics of Vagus Nerve Stimulation and Induced Arrhythmias. A:
Mean frequency of vagal nerve stimulation (VNS) during induction of atrial
fibrillation (AF) and atrial flutter (AFl). B: Mean dominant frequency of AF and AFl
induced by burst pacing during VNS. C: Effect of VNS on atrial effective refractory
period (ERP). All values are reported as mean ± standard deviation.

5.5.2 Shock Excitation Threshold

Atrial and ventricular SETs were measured for each defibrillation vector and for
both polarities during sinus rhythm before induction of AF. A representative
example of SET measurement is shown in Figure 5.4. In this case, a 0.5 V, 10
ms shock failed to capture atrial or ventricular tissue (Figure 5.4A), while a 1 V
shock captured the atria but not the ventricles (Figure 5.4B). Increasing the
shock amplitude to 6.5 V captured both atria and ventricles (Figure 5.4C).

Changing shock polarity did not significantly alter atrial or ventricular SET
(Figure 5.5A). The atrial SET was significantly less than the ventricular SET for
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each vector tested (Figure 5.5B). This finding enabled the application of ST2
shocks above the atrial SET and below the ventricular SET delivered outside the
ventricular refractory window without inducing ventricular tachycardia or
fibrillation (VT or VF, respectively).
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Figure 5.4. Determination of Atrial and Ventricular Shock Excitation Thresholds. An
example of the surface electrocardiogram (EKG), atrial (AEG) and ventricular (VEG)
electrograms, respectively, recorded during the measurement of atrial and
ventricular shock excitation thresholds (SET) for shock vector RAA>LAA is shown.
A: 0.5 V shock captured neither atrial nor ventricular tissue. B: 1 V shock captured
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atrial but not ventricular tissue. C: 6.5 V shock captured atrial and ventricular tissue.
A, atrium; V, ventricle.

Figure 5.5. Shock Excitation Thresholds are Independent of Polarity and
Electrode Position. Mean atrial and ventricular shock excitation threshold (SET) is
shown for different electrode sizes and individual vectors tested. A: Reversing
polarity of the shock vector did not reduce SET significantly. Atrial (black bars) and
ventricular (white bars) SETs from two vectors using 1.0 in diameter disc electrodes
placed on the left and right atrial appendages (LAA and RAA, respectively) is
depicted. For each vector, notation is anode > cathode. B: Atrial and ventricular
SETs for the three vectors tested using 0.5 in diameter disc electrodes and a 4F CS
lead with two 1 in coils. C: Impedances for each vector tested. Note that the
RAA>LAA impedance using 0.5 inch electrodes (0.5”) was larger than for 1.0 inch
electrodes (1”), resulting in increased ventricular SETs for the 0.5 inch electrodes.

5.5.3 Testing MP versus BP and single versus multiple
shocks

Atrial DFTs for ST1 shock waveforms are summarized in Figure 5.6, with peak
shock voltage in the upper panel and total energy in the lower panel. Total energy
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was calculated as the sum of the energies of individual shocks. In all cases, AFl
was easily terminated by a single BP shock at 0.0003 ± 0.0001 J or antitachycardia pacing (ATP) with successful rate of 100% for each therapy. For
termination of AF, the atrial DFT of 1BP shock was significantly lower than that
of 1MP shock (0.55 ± 0.1 J vs. 1.38 ± 0.31 J, p =0.004). Similarly, the atrial DFT
of 2BP shocks was significantly lower than that of 2MP shocks (0.72 ± 0.19 J vs.
1.92 ± 0.56 J, p < 0.001). Interestingly, the atrial DFT of 4BP shocks was
significantly higher than that of 2BP (1.50 ± 0.50 vs. 0.72 ± 0.02 J, p = 0.018),
since the voltages required to terminate AF were similar for 2, 3 and 4 BP shocks.
Additionally, though the efficacy of 1 BP shock was lower compared 2 BP shocks,
the peak voltage was significantly higher. Therefore, we deemed 2 BP shocks to
be the optimal waveform and chose it as the first stage (ST1) of subsequent
multiple-stage therapy.

Figure 5.6. Peak Voltage and Total Energy of Stage 1 therapies. For each therapy
tested in Stage 1 (ST1), peak voltage (A) and total energy (B) is shown. MP,
monophasic shock; BP, biphasic shock; the number preceding the shock type
describes the number of shocks delivered, e.g., 1MP denotes a single MP shock while
4BP denotes four sequential BP shocks.
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5.5.4 Development of a low energy multiple stage
defibrillation therapy

2BP shocks (ST1) proved an optimal compromise with respect to peak voltage
and total energy for cardioversion of AF in this model. Next, we asked whether
additional stages, such as sub-ventricular excitation shocks (ST2) and ATP (ST3)
further lowered the atrial DFT. Figure 5.7 shows a representative example of AF
termination by one-stage, two-stage, and three-stage therapies and the
corresponding atrial DFTs. The summarized results are shown in Figure 5.8.
2BP shocks followed by ATP (S1+S3) reduced the atrial DFT to 0.51 ± 0.46 J
compared to 0.95 ± 0.32 J for ST1 alone (shock vector RAA>LAA, p=0.006).
Significantly, atrial DFT was dramatically reduced further by the combination of
2 BP shocks followed by sub-ventricular SET shocks and then ATP
(ST1+ST2+ST3). This “three-stage therapy” reduced the atrial DFT by nearly
four-fold to 0.19 ± 0.12 J (vs 0.95 ± 0.32J for ST1 alone, p<0.001). The threestage therapy was then tested across multiple vectors.
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Figure 5.7. Representative Atrial Electrograms of AF Terminations. For each panel,
peak voltage in Stage 1 (ST1) and total energy is denoted above the corresponding
atrial electrogram. The time that each individual therapy was delivered is indicated
with an arrow. A: ST1 therapy of two 100 V biphasic shocks (total energy 1.14 J)
terminated AF. B: Stage 1 plus Stage 3 (ST1+ST3) lowered the peak voltage of ST1
to 70 V and the atrial defibrillation threshold (DFT) to 0.56 J. C: Three‐stage therapy
(ST1+ST2+ST3) dramatically reduced the total energy to 0.05 J and the peak voltage
of ST1 to 20 V.

5.5.5 The relationship of shock vector to atrial DFT

We applied the three-stage therapy across three vectors: LAA-RAA, RAA to CSd,
and CSp-LAA. Surprisingly, we detected no significant difference in atrial DFT
(Figure 5.8D).
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Figure 5.8. Atrial DFTs for each Shock Vector tested. Atrial DFTs of ST1, ST1+ST3
and ST1+ST2+ST3 are shown for each vector tested in total energy. A: Shock vector
SVC>CSd. B: Shock vector CSp>LAA. C: Shock vector RAA>LAA. D: Atrial DFT of
Three‐Stage therapy (ST1+ST2+ST3) did not significantly differ with respect to
shock vector tested. SVC, superior vena cava; CSd, distal coronary sinus; CSp,
proximal coronary sinus; LAA, left atrial appendage; RAA, right atrial appendage.
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5.5.6 Safety considerations

Two out of a total of 3444 AF termination attempts induced VF. One episode was
caused by improperly triggered ST1 application (not delivered on the R-wave)
due to unexpected noise in the ventricular electrogram.

Adding an R-wave

recognition algorithm in the trigger function and using the surface ECG as the
trigger input when the signal-to-noise ratio of ventricular electrogram was poor
overcame this problem. The second VF episode was induced by ST2 shocks when
the applied shock amplitude was very close to the ventricular SET. This problem
was avoided in subsequent trials by strictly limiting the amplitude of ST2 shocks
to below 50% of the ventricular SET.

5.6 Discussion

The main findings of the present study are as follows:
1. Single and multiple biphasic shocks in ST1 were significantly more
efficacious at terminating AF than the same number of monophasic
shocks,
2. Increasing the number of biphasic shocks in ST1 above two did not
decrease the atrial DFT in this model,
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3. A three-stage therapy ST1+ST2+ST3 significantly reduced the atrial DFT
compared to one-stage (ST1) and two-stage (ST1+ST3) therapies,
4. Three tested defibrillation vectors (RAA-LAA, RAA-CSd, LAA-CSp) were
equally efficacious for all tested combinations of stages of therapy (ST1,
ST1+ST3 and ST1+ST2+ST3).

A prevailing theory is that AF is induced and maintained by a single or a small
number of stable, self-sustained mother rotors giving rise to exceedingly high
frequency excitation, with resultant fibrillatory conduction in the atria.136 Rotors
are organized around phase singularities which tend to anchor to anatomical or
functional syncytial heterogeneities.52 Attempts to optimize electrotherapy of
fibrillation should be based on directly targeting the phase singularities.136-138 We
have, however, demonstrated that electrotherapy may fail to defibrillate despite
successful termination of phase singularities that maintain the ongoing
arrhythmia.

This occurs because defibrillation simultaneously terminates

existing phase singularities while inducing new phase singularities via the virtual
electrode induced phase singularity mechanism.139 Biphasic shocks with
appropriate energy ratios between the first and second phases can create
homogeneous post-shock transmembrane polarization and phase distribution,
which reduces the probability of inducing new phase singularities.

44

Therefore,

an optimized biphasic shock therapy was proven safe and reliable in treating
AF.122
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The atrial DFT of a conventional single biphasic shock remains above the human
pain threshold.125-130 This fact greatly limits implantable device therapy for
cardioversion of AF.

High voltage shocks also cause electroporation140 and

impair efferent sympathetic neural function.141 The three-stage AF therapy
developed and tested in the present study is below the thresholds of
electroporation and nerve damage.140-142 Most importantly, the energies and
voltages necessary to cardiovert AF using multi-stage therapy are well likely
below the human pain threshold,12 making realistic the possibility of an
implantable device for defibrillation of AF.

We previously found that multiple monophasic shocks achieve lower
defibrillation thresholds than biphasic shocks in an in vitro model of VT in
chronically infarcted rabbit hearts.109 In contrast, this study shows that multiple
biphasic shocks are superior for the defibrillation of AF, a finding that is
consistent

with

defibrillation.31,

32

the

studies

of

traditional

high

energy,

single

shock

The apparent discrepancy in findings between these studies

may be explained by different mechanisms of low-energy defibrillation in these
different tachyarrhythmias. VT, in the rabbit model, was maintained by a single
rotor with phase singularity attached to a chronic infarction scar. Successful
multiple-shock low-voltage defibrillation was achieved by maintaining a small
region refractory in the reentry circuit via the VEP effect induced by monophasic
shocks until the wave front crashed into this refractory region and terminated.
Accordingly, the second phase of biphasic shocks reverses the VEP effect of the
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first phase and is therefore disadvantageous.109 Hence, biphasic shocks have
higher DFTs compared to monophasic shocks for termination of VT. In contrast,
AF is sustained by multiple rotors with different frequencies, phases, and
anatomical locations. Therefore, extinguishing all existing rotors is fundamental
to the defibrillation of AF.135 This is better achieved by biphasic shocks, which
create a more homogenous VEP pattern than monophasic shocks, and provides a
mechanistic explanation of our findings in the present study.

Another important difference between the defibrillation of VT versus AF is the
optimal number of shocks. In a canine infarct model of VT, we found that three
monophasic shocks had the highest DFT, while ten monophasic shocks applied
within two VT cycles had the lowest DFT compared to one, three, five, and seven
monophasic shocks applied within one VT cycle.99 In the present study, we
demonstrated that applying more than two biphasic shocks in ST1 did not lower
the DFT. This difference suggests fundamental differences in the mechanisms of
defibrillation of a relatively slow and more organized VT wave front versus a
faster and more disorganized collection of wave fronts seen in AF; a longer train
of shocks in a short interval could lead to defibrillation failure not by failing to
terminate the existing disorganized wave fronts per se, but rather, by inducing
new wave fronts.74

Moreover, from a neurological point of view, a smaller

number of shocks is advantageous in developing a painless AF cardioversion
strategy, as perceived pain increases with increasing number of shocks.143
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Our three-stage therapy significantly lowers the energy for cardioversion of AF by
application of three different stages of therapy, which we mechanistically relate to
the: (1) unpinning of wave fronts that maintain AF, (2) prevent re-repinning of
wave fronts to tissue heterogeneities such as scar, and (3) annihilation of
remaining wave fronts. The unpinning stage uses multiple pulses aiming to
unpin the reentry from the stabilizing resistive heterogeneity. The applied electric
field creates stronger virtual electrode polarization at tissue heterogeneities,
which causes excitation and then unpinning of the reentry.51,

52

However, this

stage leaves behind a number of unpinned phase singularities which could then
re-pin to heterogeneities and perpetuate AF. Thus, the anti-repinning stage likely
prevents the meandering singularities from anchoring back to the tissue
heterogeneities by applying an entrainment shock train.144 After the first two
stages, the last stage adopts anti-tachycardia pacing to drive the remaining
reentry circuits to the boundaries of the atria, i.e., tricuspid or mitral annulus,
vena cavae, or pulmonary veins, thereby annihilating the arrhythmia to restore
sinus rhythm109, 135, 145.

AF is rarely fatal, yet atrial defibrillation stimuli could lead to VF, as was found
earlier146 and in our study. Accordingly, the safety of any atrial defibrillation
therapy must be considered the highest priority. Our study revealed several
techniques to improve safety. Synchronization of the first stage shocks to the Rwave to deliver it within the ventricular ERP is critical to avoiding potentially
lethal post-shock ventricular arrhythmias. Similarly, the shock amplitude of the
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second stage has to be significantly below the ventricular shock excitation
threshold.

We found that delivering the second stage below 50% of the

ventricular SET provided an adequate safety margin and prevented unintended
ventricular excitation.

Prior studies of atrial defibrillation delivered shocks from a CS coil to an RA coil
positioned along the lateral wall in order to minimize damage to the sinoatrial
and atrioventricular nodes.147 Our studies indicated that a defibrillation vector
involving the coronary sinus may enhance the probability of inducing VF due to
the relative ease of exciting ventricular tissue from the canine CS. In contrast, the
human coronary sinus is better insulated from the ventricular myocardium due
to a thicker fatty and fibrotic tissue barrier that is more robust than that of
canines (data not shown). Nevertheless, due to the larger size of human coronary
sinus anatomy, the migration of such a lead after implantation could cause
unintended ventricular capture during Stages 2 and 3 of the three-step therapy.
Such migration may be prevented by cautious implantation to avoid placing the
CS lead into sub-vessels from which the coil may easily migrate out of, and by
designing leads that more stably maintain their position after implant.

Further reductions in atrial defibrillation energy may be achieved by thoughtful
engineering.

Larger impedances require higher voltage shocks to deliver

adequate defibrillation energy, yet large voltage shocks are more likely to be
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painful. Previous studies showed that increasing electrode surface area by using
multiple cathode or anode electrodes can significantly reduce the overall
impedance.148

Importantly, such a reduction would also decrease the peak

voltage necessary for defibrillation, which is directly linked to pain sensation.
Another strategy is to deliver sequential shocks across multiple vectors using
several different pairs of electrodes.148-150 This strategy could also be used to
lower DFTs by eliminating the region of low field gradient created between two
electrodes that are electrically tied together. In addition to multiple stage therapy,
the engineering techniques discussed here may be crucial to keeping the atrial
DFT under the pain threshold and should be explored in future studies.

5.7 Conclusions
In the present study, we found that multiple biphasic shocks were significantly
more efficacious for cardioversion of AF than monophasic shocks, and that two
sequential biphasic shocks was optimal in terms of atrial DFT and peak voltage.
We also showed that a novel three-stage therapy we achieved the lowest atrial
DFT. Importantly, the atrial DFT of three-stage therapy is at or below the pain
threshold (0.19 ± 0.12 J). Finally, our study demonstrated that defibrillation
vector did not significantly alter atrial DFT. Based on this study, we conclude
that three-stage therapy may allow pain-free cardioversion of atrial fibrillation.
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6

Conclusions and Future Directions

6.1 Concluding Remarks

This dissertation first explored the mechanisms of maintenance and termination
of ventricular arrhythmias in the ex-vivo whole rabbit heart model of chronic
myocardial infarction using panoramic optical mapping technique, as presented
in Chapter 3. It has been shown that the effective size and arrhythmia wave
propagation patterns of rabbit heart are the most similar to that of the human
heart. Moreover, the size of the rabbit hearts allows us to use the Langendorff
perfusion system to perfuse the whole heart and to apply panoramic imaging
technique to directly visualize the effect of the electric shocks on the whole
epicardium surface. These techniques facilitate the study of mechanisms of
arrhythmia in this model as well as accordingly development of more efficient
defibrillation waveforms with low defibrillation thresholds.

A thin layer of surviving endocardial border zone is typical in this model. We
showed that the infarct and the border zone played an important role in
stabilizing and sustaining the reentry VT in the setting of chronic myocardial
infarction. This finding is consistent with previous theoretical and experimental
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studies as well as clinical observations that VT is stabilized and sustained by
functional or anatomical heterogeneity. Sustained monomorphic VT occurs in the
absence of acute ischemia when the patients have an old myocardial scar. In this
rabbit model, we found antitachycardia pacing inefficient in termination of VT.
We also found a phase-dependent mechanism of VT termination by a single
biphasic shock, which is commonly used by current ICD therapy. This finding is
consistent with previous finding about the efficacy of a single monophasic shock
in termination of VT in the same model. The minimum and maximum CVT were
significantly different in all eight hearts, where the maximum vs. minimum CVT
of 1BP applied at various phases was 8.6 ± 1.7 vs. 3.7 ± 1.9 V/cm, respectively
(p=0.0013). Moreover, we found that the minimum and maximum CVT of a
single monophasic shock were similar to that of a biphasic shock in termination
of VT. For both shock waveforms, the optimal phase with the minimum CVT
varied with different hearts, different VT morphology. More extensively, it could
change with different sizes and locations of the infarction, different sizes and
locations of defibrillation electrode, etc. Therefore, clinically, this optimal phase
is impossible for us to measure.

Based on the mechanism of VT termination by a single shock, we generated an
idea of using sequential multiple shocks that cover all the phases in one VT cycle
length so that we can achieve the minimum defibrillation energy without the
need to determine the optimal phase. We tested the multiple shock therapy in the
same rabbit model with chronic infarction and compared the efficacy of multiple
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monophasic shocks with multiple biphasic shock. We found that CVT of five
monophasic shocks is similar to the minimum CVT of a single biphasic shock at
4.3 ± 1.9 vs. 4.9 ± 2.7 V/cm, respectively (p=0.37). This suggests that we achieved
the minimum CVT of a single shock successfully using the multiple pulse therapy
without determining the optimal phase.

We studied the mechanism of termination of VT by multiple shock therapy and
found that the multiple shocks applied within one VT cycle length terminated VT
by maintaining virtual cathodes at certain areas of the reentrant circuit. The
refractory period was prolonged at those areas and the reentrant wave front was
haunted and vanished when propagated to the refractory areas. Then the reentry
was unpinned from the anchoring site. To our surprise, in contrast to the
conventional single shock defibrillation where the biphasic waveform is superior
than monophasic waveform, we found that the multiple monophasic shocks had a
significantly higher efficacy than multiple biphasic shocks in termination of VT.
Based on the VEP theory of defibrillation, we know that biphasic waveform
generate no VEP because the VEP pattern created by the first phase of the
biphasic shock is reversed by the second phase. However, low-voltage multiple
shock therapy terminates VT by maintaining the virtual cathodes throughout a
VT cycle length. Therefore, multiple monophasic shocks are more efficacious
than multiple biphasic shocks for this purpose. We could also conclude that both
panoramic optical mapping technique and VEP theory of defibrillation are
incredibly crucial in studying the mechanisms of the defibrillation and in

114

developing new efficacious defibrillation waveforms with low defibrillation
thresholds.

The size of a rabbit heart makes it an optimal model to study the mechanism of
low-voltage defibrillation in the Langendorff perfusion system and panoramic
imaging system. However, it is still an ex-vivo experimental model. The
defibrillation electrodes that we used are two rectangular mesh electrodes
parallel to each other in the perfusion chamber. The defibrillation thresholds
could be only presented using the intensity of the electric field across two
electrodes instead of the real energy that delivered to the heart.

In order to validate the multiple shock therapy, we used a more clinically relevant
model, which is canine hearts with healing myocardial infarction in vivo, as
described in Chapter 4. In this model, the myocardial infarction was created by 2
hours’ LAD ligation. Four days later, the defibrillation study was performed. This
model has been shown to have an epicardial infarction border zone, which is
similar to that in human heart. The sized of a dog heart is more close to that of
the human heart. We adopted multi-electrode mapping technique to study the
mechanism of arrhythmia. We found that the mechanism of sustained VT in this
model is mainly monomorphic Figure-of-eight reentry with a common pathway
or isthmus located at the infarction border zone. We used a 8F RV coil and a
posterior LV patch as the reference electrode. We tested multiple shock therapy
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with different number of shocks and found that ten monophasic shocks applied
within two VT cycle length has the lowest CVT (0.04 ± 0.02 J), compared to
three, five, and seven shocks that applied within one VT cycle length. This might
be due to the reinforcement of VEP effect of multiple monophasic shocks in two
VT cycles. This study optimized the multiple shock therapy for termination of VT
and confirmed it as a low-voltage, low-energy defibrillation therapy in an in vivo
large animal model.

Other than low-voltage defibrillation therapy for ventricular arrhythmias was
studied and developed in this dissertation, we also aimed to develop a lowvoltage defibrillation therapy for atrial fibrillation to make the pain-free atrial
ICD therapy possible. The study was presented in Chapter 5, on an in vivo canine
model of vagally-mediated AF. We took advantage of AF being nonlethal and
developed a multi-stage therapy. We compared it to multiple shock therapy, and
tested monophasic and biphasic waveforms for the first-stage therapy. Different
than the multiple shock therapy for VT, multiple biphasic shocks had
significantly lower atrial DFT than multiple monophasic shock, which is
consistent with the finding for traditional a single shock defibrillation. This is
mainly due to different mechanisms of the arrhythmias. Reentry VT in the last
two animal models were sustained by a single mother rotor or a common
pathway. In contrast, AF in this model is sustained by multiple rotors with
different frequencies, phases, and anatomical locations. Therefore, extinguishing
all existing rotors is fundamental to the defibrillation of AF. This is better
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achieved by biphasic shocks, which create a more homogenous VEP pattern than
monophasic shocks, and provides a mechanistic explanation of our findings in
the present study.

Another important difference between the defibrillation of VT versus AF is the
optimal number of shocks. In a canine infarct model of VT, we found that less
(three) monophasic shocks had the highest DFT, while more (ten) monophasic
shocks applied within two VT cycles had the lowest DFT compared to one, three,
five, and seven monophasic shocks applied within one VT cycle. In the present
study, we demonstrated that applying more than two biphasic shocks in the firststage did not lower the DFT. This difference suggests fundamental differences in
the mechanisms of defibrillation of a relatively slow and more organized VT wave
front versus a faster and more disorganized collection of wave fronts seen in AF;
a longer train of shocks in a short interval could lead to defibrillation failure not
by failing to terminate the existing disorganized wave fronts per se, but rather, by
inducing new wave fronts. Moreover, from a neurological point of view, a smaller
number of shocks is advantageous in developing a painless AF cardioversion
strategy, as perceived pain increases with increasing number of shocks.

We validated that multi-stage therapy had a significantly lower atrial DFT (0.19 ±
0.12 J), compared to one-stage and two-stage therapy in all three defibrillation
vectors that we tested. We didn’t find any significant difference of multi-stage
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therapy in the three vectors. With this energy level required for atrial
defibrillation by the multi-stage therapy, we suggest that the pain-free atrial
defibrillation device is possible.

6.2 Future Directions

6.2.1 Mechanisms of Defibrillation using Multi-stage Therapy
for AF

The multi-stage therapy developed in this dissertation had achieved significantly
low-energy for atrial defibrillation, which might be below patient’s pain
threshold. However, the mechanism of atrial defibrillation using multi-stage
therapy remains unclear. In order to study the mechanism, we need to take a step
back from the in vivo animal model to the ex vivo animal model, such as
Langendorff-perfused whole rabbit heart or isolated canine atria. These two
animal models would allow us to apply optical mapping technique to visualize the
effect of every stage during the electrotherapy. It will give us a better
understanding about how the multi-stage therapy works based on the VEP
hypothesis of defibrillation. With this knowledge, we can optimize the multi-stage
therapy, for example, the intervals between each shocks in the first and the
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second stages, and delays between each stage, the number and duration of
stimuli for each stage, etc. All these parameter could be explored and optimized
in the Langendorff-perfused hearts.

At the same time as studying the mechanism of termination of AF by the multistage therapy, we could also work on the automation of the therapy delivery
algorithm. For example, we need to be able to perform real-time FFT analysis to
determine the dominant frequency of AF before each stage of the electrotherapy
in order to determine whether the conversion succeeds or to determine the
parameters for the next multi-stage therapy when the conversion fails.

Although we found that there are no significant difference in the atrial DFT of
three different defibrillation vectors in the open chest canine model of vagallymediated AF, it would be interesting to test the atrial DFT of rotating-field for the
first-stage in the multi-stage therapy. Rotating-field was designed and is ready to
be used for that purpose. We can deliver the multiple (two to three) shocks in the
first-stage using different defibrillation vectors for each shock to create a electric
field that is rotating around the atria to create more homogeneous VEP on atria
tissue that might enhance the efficacy to eliminate mother rotors that sustain AF.
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6.2.2 Low-voltage Defibrillation therapy for VT in canine
model of healing infarct

In this model, we found that the anti-tachycardia pacing is ineffective. However,
we did not combine the multiple shock therapy with the anti-tachycardia therapy
together. It would be interesting to test the multi-stage or two-stage therapy (first
stage and third stage of the multi-stage therapy) in the in vivo canine model of
healing infarct and ex vivo Langendorff-perfused canine hearts with healing
infarct to use optical mapping to study the mechanism of termination of VT using
multi-stage therapy. Especially, it would be interesting to see whether there is any
difference in the efficacy of multi-stage therapy with respect to the two different
types of arrhythmia: AF and VT.

Moreover, we used an implanted RV coil to epicardial LV patch as the
defibrillation vector to test the multiple shock therapy in the canine healing
infarction model. However, this is not a clinically possible electrode configuration
for implantation. We should test the multiple shock or multi-stage therapy using
a transvenously implantable vector system, for example, implanted RV coil to
implanted cononary sinus coil. We could also use the same real-time FFT
technique to the VT study for automatic measurement of the VT cycle length for
setting the parameters of the therapy.
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6.2.3 Implantable Low-voltage Atrial Defibrillation Therapy
in canine hearts

For the multi-stage we developed and validated in the open chest canine hearts,
we used a vagally-mediated model of acute AF, which doesn’t involve atrial
remodeling. However, atrial remodeling occurs most of the patients that have
persistent or permanent AF. In order to reproduce the same substrates setting
that sustained AF clinically, we could test the multi-stage therapy in a more
clinically relevant model, chronic rapid atrial pacing canine model of AF. This
model develops atrial electrical and mechanical remodeling over time. The
mechanisms of AF might be different in the acute and the chronic model. Thus, it
will be interest to test and optimize our multi-stage therapy in the chronic model.

In our acute AF model presented in this dissertation, we still used disc electrode
that sutured to the epicardium for RAA, LAA, and SVC. In the chronic rapid atrial
pacing model, we could transvenously implant all the defibrillation leads during
the pacemaker implant and test our multi-stage therapy in the close-chest
animal. By doing that, we could perform several defibrillation studies to the same
animal at different time points. The chronic rapid atrial pacing induced atrial
remodeling and the transnenous lead system is more clinically relevant. We could
also try to decrease the impedance for each defibrillation vector to lower the
121

energy required for defibrillation. We could use a joint vector, which is
combining two coils as one electrode to increase the surface area of the electrode.
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Appendix A
A.1 Multi-Stage Defibrillation Therapy
A.1.1 Hardware

A customized defibrillator was designed to allow us to deliver arbitrary
defibrillation waveforms. It is comprised of functional blocks of sensing,
amplification, recording, therapy generation, and therapy delivery. EKG, Atrial
electrogram (AEG) and ventricular electrogram (VEG) will be continuously
recorded during each defibrillation study. The cycle length or dominant
frequency of the arrhythmia will be determined, according to which, the
parameters of the three-stage defibrillation therapy will be adjusted. Customized
LabVIEW program and a data acquisition system (PCI-6221, National
Instruments Corp.) are used to generate shock waveform and pacing waveform
for the therapy. The delivery of the therapy is triggered by R wave or VEG. The
electric shocks are delivered through two kepcos power supplies (BOP 100- 4M,
Kepco Inc.) connected in series or in parallel to generate an maximum output of
(4 Amp, 200 V) or (8 Amp, 100V), respectively. The pacing stimuli are delivered
through a stimulus isolator (A385, World Precision Instruments, Inc.) with
adjustable current output.
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Figure A1. An illustrating diagram of the custom defibrillator using for AF
defibrillation. Two analog waveforms and several digital signals were generated for
shock, pace, and vector control.

Figure A2. Photograph of defibrillation system.
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A.1.2 Three-stage therapy LabVIEW

A LabVIEW program was written for one‐stage, two‐stage, or three‐stage
defibrillation therapy. All the inter‐stage intervals and the intra‐stage intervals can
be set according to the cycle length of the arrhythmia. Monophasic or biphasic
waveform with different pulse width and tilt can be selected for shock waveforms.
Number of shocks or pacing stimuli can be varied by the user too.

Figure A3. LabVIEW program for three‐stage defibrillation therapy.
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A.1.3 Data analysis software LabVIEW

A LabVIEW program is written for display of EKG, atrial, ventricular electrograms,
shock and pacing stimuli applied that were recorded continuously during the
experiment. All the electrograms are synchronized and any arbitrary interval could
be measured directly using two cursors.
There are two major functions of this program. First, it could determine the
dominant frequency of the tachyarrhythmia using Fast Fourier Transfrom (FFT) and
peak detection algorithm of the electrogram for a certain period time confined
within two cursors. Second, it could detect the beginning and the end of the multi‐
stage therapy even with multiple shocks and determine the dominant frequency
before and after the therapy for each delivered therapy in the whole data file and
output the results into an excel file.

126

Figure A4. LabVIEW program for electrogram visualization and electrogram
analysis.

A.2 Rotating-field Defibrillation Therapy
A.2.1 Hardware

This defibrillator can rotate the electric shocks among different defibrillation
vectors within milliseconds. Each vector is controlled by a pair of relay which is
timed using a digital output from the computer.
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Figure A5. Sratch of the design of relay box for the rotating‐field defibrillator. It has
three pairs of relay now. It can be as many as wanted for the number of
defibrillation vectors. Usually three defibrillation vectors can cover the three‐
dimensions of the electric field.

A.2.2 Rotating-field Therapy LabVIEW

This program is meant to be used altogether with NI Multifunction DAQ board,
switches box, and Kepco machines for generation of several pulses of which each
pulse can be passed through different electrodes available. The program is
essentially can be divided into two parts, one part to generate the pulses and the
other to generate the signals to control the switches. The pulses will be sent
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through the analog outputs of the NI Multifunction DAQ board after a trigger is
passed through the digital input of the Multifunction DAQ board. Subsequently,
the pulses are passed to the Kepco machines for amplifying purpose. The output
from the Kepco will then be sent to the switches box where the relays are
controlled by the digital output signals of the Multifunction DAQ board. The final
output can then be retrieved from the electrodes connected to the relay box.

Figure A6. LabVIEW program for rotating‐field defibrillation therapy.
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